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ABSTRACT 
 
 
The mammalian transforming growth factor β (TGFβ) superfamily comprises over 40 
ligands, which are multifunctional regulators of cellular growth, differentiation and 
death. These factors signal by binding to a limited number of highly conserved 
transmembrane type I (activin receptor-like kinase, ALK) and type II receptor 
serine/threonine (ser/thr) kinases. Intracellularly the signal is transmitted to the 
nucleus by phosphorylated Smad signaling proteins. During the course of this thesis 
project we first determined the chromosomal loci of the type II activin receptors, the 
type I receptor ALK7 and the activin binding protein follistatin. An attempt to clone 
new ser/thr kinases resulted in the identification and isolation of the human ALK7 
cDNA, the mRNA of which was shown to be widely expressed in the adult human. 
Furthermore, adenovirus-mediated overexpression of the constitutively active ALK7 
resulted in specific phosphorylation of Smad2. 
 
Inhibin hormones, which belong to the TGFβ superfamily, are produced in the ovary 
and act as negative regulators of follicle stimulating hormone (FSH) release from the 
anterior pituitary. We set out to study the involvement of different TGFβ superfamily 
members and their signaling components in the complex regulation of intraovarian 
inhibin subunit expression. The bone morphogenetic proteins (BMPs) form the largest 
subgroup within the TGFβ superfamily and we showed that cultured human 
granulosa-luteal (hGL) cells express all components needed for BMP signaling and 
further, that recombinant BMPs selectively induce the expression of the inhibin βB-
subunit in these cells leading to a production of dimeric inhibin B. Using recombinant 
adenoviruses we selectively overexpressed various components of the TGFβ 
superfamily signaling machinery in hGL cells and showed that overexpression of 
constitutively active ALK1-7 and Smad1 and Smad2 proteins stimulates the 
production of inhibin B. Next, using cultured rat granulosa cells, growth 
differentiation factor-9 (GDF-9), another member of the TGFβ superfamily, was 
shown to stimulate the expression of all three inhibin subunits resulting in a 
production of dimeric inhibin A and B. Finally, GDF-9 stimulation of the rat 
granulosa cells was shown to induce Smad2 phosphorylation, indicating that either 
ALK4, ALK5 or ALK7 might function as a putative type I receptor for GDF-9. 
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INTRODUCTION 
 
 
In mammalian organisms the various members of the transforming growth factor β 
(TGFβ) superfamily are known to be involved in most aspects of cellular growth, 
differentiation and death. Although most of these polypeptides differ clearly in 
function they share a limited number of receptors. The receptor molecules are highly 
conserved transmembrane serine/threonine kinases, which can be divided in two 
distinct groups based on function and structure, the type I (or activin receptor-like 
kinases, ALKs) and type II receptors. Upon ligand binding these binding moieties 
form tetrameric complexes consisting of two type II and two type I receptors, after 
which Smad signaling proteins are activated by the type I receptors. Activin and 
TGFβ type I receptors specifically activate a different set of Smad signaling proteins 
than do the bone morphogenetic protein (BMP) type I receptors. In addition, there are 
inhibitory Smads which oppose the signaling cascade. Several of the knockout mouse 
models generated for the serine/threonine kinase receptors and Smads either die 
during embryonic development or show severe developmental defects, indicating that 
the loss of one signaling component can not necessarily be compensated for by 
another (reviewed in Massagué et al., 2000). 
 
The mammalian ovary is responsible for producing fertilizable oocytes and female sex 
steroids. In addition to the pituitary gonadotropins follicle stimulating hormone (FSH) 
and luteinizing hormone (LH), the TGFβ superfamily member growth differentiation 
factor-9 (GDF-9) has been shown to be indispensable for successful murine 
folliculogenesis (Dong et al., 1996), a process where ovarian primordial follicles are 
recruited to grow (reviewed in Findlay et al., 2002; Matzuk et al., 2002). However, 
even though GDF-9 has recently been reported to signal via the BMP type II receptor 
(BMPRII) (Vitt et al., 2002), its type I receptor(s) remains yet to be characterized. 
Consequently, prior to our studies it was not known whether stimulation of granulosa 
cells with recombinant GDF-9 would lead to Smad activation. 
 
The inhibins are TGFβ family members produced by ovarian somatic cells, and in 
addition to auto/paracrine intraovarian effects these hormones are capable of 
suppressing FSH release from anterior pituitary cells. During the human menstrual 
cycle the two main forms of inhibin in the serum, inhibin A (a dimer of the inhibin α- 
and βA-subunits) and inhibin B (a dimer of the inhibin α- and βB-subunits) fluctuate in 
specific and distinct patterns. It has previously been shown using cultures of human 
granulosa-luteal (hGL) cells that the expression of different inhibin subunits can be 
specifically regulated by various growth factors, including activin and TGFβ 
(reviewed in Findlay et al., 2001). Even so, the possible involvement of various 
BMPs, type I receptors and downstream Smad signaling proteins in the complex 
regulation of inhibin subunit expression had not been addressed prior to this study.  
 
The following review of the literature first focuses on giving a background on the 
TGFβ superfamily and the signaling machinery used by its members. Thereafter the 
roles of ovarian BMPs and the regulation of inhibin subunit expression in the ovary 
will be discussed. 
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REVIEW OF THE LITERATURE 
 
 
1. GENERAL CHARACTERISTICS OF THE TRANSFORMING GROWTH 
FACTOR β SUPERFAMILY 
 
 
1.1. Historical background 
 
Of the approximately 30 000 human genes (Lander et al., 2001) some 40 form a group 
known as the transforming growth factor β (TGFβ) superfamily. The prototype for 
these polypeptides, TGFβ, was isolated in the beginning of the 1980s (Roberts et al., 
1981; Derynck et al., 1985) and since then the family of known members has rapidly 
expanded to its present size. TGFβ was originally named after its ability to cause a 
phenotypic transformation of cultured epithelial cells. Soon later, it was shown to 
inhibit the growth of most epithelial and haematopoietic cells and to regulate the 
production of extracellular matrix by mesenchymal cells. The effects of a specific 
TGFβ family member appeared to vary depending on the particular type and state of a 
cell. At present the various members of the TGFβ superfamily are acknowledged to 
participate in almost all forms of biological events including cellular growth, 
differentiation, morphogenesis, sexual development, fertility and apoptosis. Based on 
structural similarities the different polypeptides of the TGFβ superfamily are divided 
into several subgroups. These include the TGFβs, the activins and inhibins, the bone 
morphogenetic proteins (BMPs) and growth differentiation factors (GDFs), and a 
heterogeneous group consisting of more distantly related factors such as anti-
Müllerian hormone (AMH) and inhibin-α (reviewed in Kingsley, 1994; Massagué et 
al., 2000) (Table 1).  
 
Table 1. Mammalian TGFβ superfamily subgroups and members. 
 
TGFβ  BMP/GDF  Activin  Others 
TGFβ1  BMP-2   Activin βA  AMH 
TGFβ2  BMP-4   Activin βB  Inhibin-α 
TGFβ3  BMP-5   Activin βC  Lefty A 
  BMP-6   Activin βE  Lefty B 
  BMP-7/OP-1     GDNF 
  BMP-8a/OP-2     Neurturin 
  BMP-8b/OP-3     Persephin 
  BMP-14/GDF-5/CDMP-1    Artemin 
  BMP-13/GDF-6/CDMP-2    MIC-1/GDF-15 
  BMP-12/GDF-7/CDMP-3    Nodal 
  GDF-1       
  GDF-3 
  BMP-9/GDF-2  
  BMP-10   
  BMP-11/GDF-11  
  GDF-8/Myostatin 
  BMP-3/Osteogenin 
  BMP-3b/GDF-10  
  GDF-9 
  GDF-9B/BMP-15 
  BMP-16, -17, -18 (unpublished patents)     
AMH, anti-Müllerian hormone; BMP,
bone morphogenetic protein; CDMP,
cartilage derived morphogenetic protein;
GDF, growth differentiation factor;
GDNF, glial derived neurotrophic factor;
MIC-1, macrophage inhibitory cytokine-
1; OP, osteogenic protein 
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1.2. Biosynthesis and structural properties of TGFβ family members 
 
All TGFβ superfamily members appear to be produced in the same manner. First, a 
larger precursor molecule of roughly 400-500 amino acids is synthesized. This 
molecule includes an N-terminal signal peptide, a pro-region and the mature C-
terminal region (Fig. 1). The signal peptide directs the protein to the endoplasmatic 
reticulum/Golgi, where the pro-region is proteolytically cleaved at a conserved RXXR 
(R, arginine; X, any amino acid) site to form the mature peptide, which is significantly 
smaller than the pro-peptide (reviewed in Kingsley, 1994). The pro-region, which is 
proposed to be needed for proper folding of the mature peptide (Gray and Mason, 
1990), is not very well conserved among different TGFβ members. However, 
orthologues of a specific ligand usually have highly homologous pro-regions. In the 
case of TGFβ1-3 and myostatin the pro-region also participates in the regulation of 
the biological activity of these peptides by forming non-covalently linked complexes 
with them, which are biologically inactive (Derynck et al., 1985; Gentry et al., 1988; 
Miyazono et al., 1988; Wakefield et al., 1988; Lee and McPherron, 2001). Another 
typical feature of most TGFβ family members is the seven conserved cysteines in 
their mature region. Six of these cysteines form a knot-like structure, whereas the 
remaining fourth cysteine is responsible for linking the two ligand monomers to each 
other, thus forming a dimer via a disulfide bond (Daopin et al., 1992; Schlunegger and 
Grutter, 1992). Interestingly, some TGFβ family proteins including the oocyte-
derived GDF-9 (McPherron and Lee, 1993) and GDF9-B/BMP-15 (Dube et al., 1998; 
Laitinen et al., 1998) lack the conserved fourth cysteine that is involved in peptide 
dimerization. It is, however, presumed that hydrophobic interactions between the two 
dimers are sufficient for linking them together. 
 
cleaving site for proteases 
 
 
 
 
 
 
 
 
Fig. 1. Schematic drawing of a representative member of the TGFβ family. The 4th 
cysteine (in black) is missing in GDF-9 and GDF-9B/BMP-15. Modified from 
Kingsley, 1994. 
 
 
1.3. The discovery of TGFβ receptors 
 
Because of the multitude of cellular events initiated by TGFβ ligands, it was 
originally believed that their signaling system would be far more complex than it 
eventually has turned out to be. In the late 1980s three different proteins were found 
to bind TGFβ1 and these were subsequently named type I, type II and type III 
receptors based on their different molecular sizes (Cheifetz et al., 1987; Boyd and 
Massagué, 1989). By using a mutant cell line resistant to TGFβ-induced growth 
inhibition it was soon shown that de facto only the type I and II receptors were needed 
for TGFβ signaling (Laiho et al., 1990). At present seven mammalian type I and five 
RXXR
Pro-region MatureNH3- -COOHSP 
COOH-, 
carboxyterminal; 
Cys, cysteine; 
NH3-, 
aminoterminal; 
SP, signal 
peptide; RXXR, 
cleaving site  
7xCys  
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type II receptors have been identified. The type I and II receptors are structurally 
related yet functionally different transmembrane ser/thr kinases, with highly 
conserved properties within the two subfamilies. These receptors appear to be 
responsible for the binding of all TGFβ superfamily members, with the exception of 
the GDNF subfamily, which signals via a receptor system consisting of the GDNF-
receptor-αs and a tyrosine kinase called RET (reviewed in Massagué, 1996; Piek et 
al., 1999b).  
 
1.3.1. Mammalian type II serine/threonine kinases 
 
In the early 1990s Mathews and Vale used expression cloning strategies to identify 
the murine type II receptor for activin, which turned out to be a receptor ser/thr 
kinase, now called ACVRII (Mathews and Vale, 1991). Soon after, a second activin 
receptor named ACVRIIB was cloned and the murine receptor was furthermore 
shown to have four alternative splicing variants with distinct affinities for activin 
(Attisano et al., 1992; Mathews et al., 1992; Hildén et al., 1994). Once more, using 
expression cloning strategies, the type II receptor for TGFβ was identified (Lin et al., 
1992) and soon after in 1994 a mammalian type II receptor for AMH was isolated 
(Baarends et al., 1994; di Clemente et al., 1994). The following year the cloning of a 
human type II receptor for BMPs was reported (Kawabata et al., 1995a; Liu et al., 
1995; Nohno et al., 1995; Rosenzweig et al., 1995). The five type II receptors consist 
of approximately 500 amino acids (1000 amino acids for a long form of BMPRII), the 
molecular weights of which vary between 70 and 85 kDa. These receptors all have N-
glycosylated cysteine-rich extracellular domains which are involved in ligand 
recognition and binding. However, the overall sequence homology between the 
extracellular domains of the type II receptors is small being the region determining 
ligand specificity. A single transmembrane domain follows the extracellular domain 
and intracellularly are the highly homologous ser/thr rich kinase domains located, 
followed by carboxy-terminal tails (reviewed in Derynck and Feng, 1997) (Fig. 2). 
The three-dimensional structure of TGFβ has been described as analogous to that of a 
“curled hand”, including fingers and a palm formed by β-strands (Daopin et al., 1992) 
and the ligand has been found to undergo a mild confirmational change in response to 
interaction with its type II receptor through its finger-like structures (Hart et al., 
2002). Recently, the crystal structures of the human TGFβRII (Hart et al., 2002) and 
ACVRII (Greenwald et al., 1999) receptor ectodomains were determined. The 
extracellular domain of ACVRII is overall quite similar to that of TGFβRII and it 
comprises seven β-strands arranged in three antiparallel sheets. Interestingly the 
topology includes a three-finger toxin fold unrelated to but reminiscent of several 
neuro- and cardiotoxins (Greenwald et al., 1999). 
 
1.3.2. Mammalian type I serine/threonine kinases 
 
After the discovery of the TGFβRII (Lin et al., 1992), there was a need to clone the 
TGFβ type I receptor, since the dual requirement of both type I and type II receptors 
for the mediation of TGFβ signals had already been postulated earlier using mutant 
cell lines resistant to TGFβ-induced growth inhibition (Laiho et al., 1990). In 1993, 
using reverse transcriptase-PCR (RT-PCR) with degenerate primers against highly 
conserved motifs within the kinase domain of the type II receptors, the existence of 
several new orphan ser/thr kinase receptors was reported (Matsuzaki et al., 1993; ten 
-Local Regulators of Inhibin Production in Ovarian Granulosa Cells 
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Dijke et al., 1993). These receptors have been named “activin receptor-like kinases” 
(ALKs), due to their high sequence similarities with the activin type II receptors. It 
became, however, soon evident that the type I receptors clearly formed their own 
subgroup, since they shared a higher degree of sequence similarity among themselves 
than with the type II receptors. The functional activin and TGFβ receptors were 
thereafter shown to be heteromeric receptor complexes consisting of a combination of 
type I and II receptors (Wrana et al., 1992; Attisano et al., 1993; Ebner et al., 1993; 
Franzén et al., 1993; Bassing et al., 1994; ten Dijke et al., 1994a). In 1994 two type I 
receptors found to bind BMP-4 and BMP-7 were reported (Koenig et al., 1994; ten 
Dijke et al., 1994b), and in 1996 a seventh mammalian ALK, denoted ALK7, was 
identified (Rydén et al., 1996; Tsuchida et al., 1996). An additional eighth ALK, 
zALK8, has been cloned from the zebrafish (Yelick et al., 1998), but it has also been 
proposed that it is actually the fish orthologue of the mammalian ALK2 receptor 
(Payne et al., 2001). All type I receptors are approximately 500 amino acid 55-65 kDa 
proteins, and they share several general structural motifs with the type II receptors. 
Like the type II receptors the ALKs have cysteine-rich extracellular domains with 
putative glycosylation sites, a short transmembrane region, and an intracellular ser/thr 
rich kinase domain. In contrast to the type II receptors, the ALKs have a functionally 
important conserved ∼30 amino acids glycine/serine (G/S) rich region with a typical 
SGSGSG sequence, denoted the GS-box, immediately preceding the kinase domain. 
The C-terminal tails of the ALKs are also substantially shorter than those of the type 
II receptors (Massagué, 1998) (Fig. 2). So far the crystal structure has been 
determined only for the ALK3 receptor ectodomain. This comprises two β-sheets and 
one α-helix and the overall structure has been compared to an open left hand (Kirsch 
et al., 2000). 
 
Fig. 2. Schematic drawing of a type II and a type I ser/thr kinase receptor.  
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1.3.3. Functional characteristics of the type I and II receptors 
 
In order to mediate signaling by TGFβ family members a tetrameric complex of two 
type II and two type I receptors has to be formed (Wrana et al., 1992; Attisano et al., 
1993; Ebner et al., 1993; Franzén et al., 1993; Yamashita et al., 1994). Even though 
the type II receptors for activin and TGFβ are able to bind their respective ligands 
alone, this is not sufficient for initiation of signal transduction. BMPs bind to both 
type I and type II receptors alone, but with rather low affinity. However, the affinity 
of BMPs for their respective receptors is greatly increased when both type I and II 
receptors are present simultaneously (ten Dijke et al., 1994b; Rosenzweig et al., 
1995). Most type II receptors, with the exception of AMHRII, bind several ligands 
and can form complexes with different type I receptors. Furthermore, the existence of 
heterotetrameric receptor complexes with different type II and type I receptors has 
also been postulated (Yamashita et al., 1994; Weis-Garcia and Massagué, 1996; 
Gilboa et al., 2000). This possibility would greatly increase the number of unique 
receptor combinations available for the TGFβ family ligands.  
 
The type II receptor, as exemplified by TGFβRII, is constitutively phosphorylated at 
several serine residues and ligand binding does not seem to affect its phosphorylation 
status (Luo and Lodish, 1997). However, upon ligand binding a receptor type I and II 
tetrameric complex is established and the constitutively active type II receptor then 
transphosphorylates the type I receptor at several serine and threonine residues in its 
GS-box (Wieser et al., 1995), and for example, ALK5 is additionally phosphorylated 
at Ser165 (Souchelnytskyi et al., 1996). The type I receptors have a Leucine-Proline 
sequence immediately preceding the GS-box, and the immunophilin FKBP12 has 
been shown to interact with this region (Wang et al., 1994; Charng et al., 1996; 
Okadome et al., 1996; Wang et al., 1996; Chen et al., 1997). The phosphorylation of 
the GS-box leads to conformational changes of the type I receptor leading to the 
release of FKBP12, which is thus prevented from further interaction with the receptor. 
The kinase of the type I receptor is then able to interact with its substrate, the different 
members of the Smad signaling protein family. Interestingly, FKBP12 null mice do 
not show impaired type I receptor signaling, indicating that other related factors may 
compensate for the loss of this protein (Shou et al., 1998). The kinase domain of the 
type I receptor contains a characteristic L45 loop, which is directly involved in Smad 
recognition (Feng and Derynck, 1997). Type I receptors have a conserved threonine, 
or glutamine, immediately before the N-terminal beginning of the kinase domain. 
When this particular amino acid is changed to the acidic aspartate (i.e., T/Q-D), the 
receptor will become constitutively active (ca) and signal independently of ligand 
binding and association to type II receptors. Similarly, by replacing a highly 
conserved lysine, which is involved in ATP binding, for arginine (i.e., K-R), the 
receptor will lose its ability to activate intracellular targets and becomes kinase 
defective (Wieser et al., 1995; Weis-Garcia and Massagué, 1996) and as a result act as 
a dominant negative mutant.  
 
1.4. Additional TGFβ family member binding proteins 
 
1.4.1. Type III receptors 
 
Betaglycan is a cell surface proteoglycan originally detected in a screen for TGFβ 
receptors. It was named the TGFβ type III receptor since its molecular size was larger 
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than those of the type I and type II receptors (Cheifetz et al., 1988). The affinity of 
TGFβ2 is normally low for its ser/thr kinase receptors. Nonetheless, after it has bound 
to betaglycan the receptor affinity is greatly increased. Furthermore, betaglycan has 
been shown to bind inhibin (Lewis et al., 2000). Endoglin is a betaglycan related cell 
surface glycoprotein that has been shown to bind various TGFβ superfamily members 
when co-expressed with ser/thr kinases (Cheifetz et al., 1992; Barbara et al., 1999). 
 
1.4.2. Other binding proteins 
 
In contrast to the TGFβs, which form latent complexes with their precursor 
molecules, this has not been shown for BMPs. Instead, several antagonistic proteins 
that are able to bind to BMP ligands have been identified. “The Differential 
screening-selected gene aberrative in neuroblastoma” (DAN) family of secreted 
cysteine-knot proteins include Cerberus, Gremlin, Caronte and Noggin. These 
proteins are able to block BMP signaling by binding to the ligand and thus preventing 
it from interacting with its receptors (reviewed in Miyazono, 2000). Furthermore, 
BMPs have been shown to interact with a pseudoreceptor called “BMP and activin 
membrane-bound inhibitor” (Bambi). Bambi was first detected in Xenopus, but based 
on structural similarities it was later recognized as being the same protein as the nma 
gene product, that had been identified earlier in a human melanoma cell line (Degen et 
al., 1996; Onichtchouk et al., 1999). Bambi is structurally a type I receptor, but it 
lacks a functional kinase domain and hence cannot phosphorylate intracellular Smads.  
 
The follistatin protein was purified in 1987 from follicular fluid and shown to be a 
secreted glycoprotein of 29-32 kDa (Robertson et al., 1987; Ueno et al., 1987). Soon 
it became evident that follistatin was able to block the effects of activins, but not 
inhibins, by binding to them through their common β-subunits (Nakamura et al., 
1990; Shimonaka et al., 1991). In addition to binding to activin and inhibin, follistatin 
has been shown to block the biological activities of several BMPs, including GDF-
9B/BMP-15 (Iemura et al., 1998; Otsuka et al., 2001a; Amthor et al., 2002). Mice 
with a targeted disruption of the follistatin gene die shortly after birth and have 
multiple developmental defects including decreased muscle mass and abnormal 
skeletal development (Matzuk et al., 1995c). The phenotype is more severe than that 
of the activin knockouts (Vassalli et al., 1994; Matzuk et al., 1995b), supporting the 
hypothesis that the bioactivity of additional growth factors might be regulated by 
follistatin in vivo.  
 
1.5. Intracellular signaling molecules 
 
1.5.1. The Smad family  
 
The human homologues to Drosophila Mad (mother against dpp) and C. elegans sma 
proteins, called Smad1-8, were identified by screening human expressed sequence tag 
(EST) databases and cDNA libraries (Sekelsky et al., 1995; Chen et al., 1996; Eppert 
et al., 1996; Hoodless et al., 1996; Lechleider et al., 1996; Liu et al., 1996; Riggins et 
al., 1996; Savage et al., 1996; Yingling et al., 1996; Zhang et al., 1996; Imamura et 
al., 1997; Nakao et al., 1997a; Topper et al., 1997). Based on structural and functional 
similarities and differences the Smad proteins fall into three classes: 
1) The receptor-regulated Smads (R-Smads) consist of two groups. Firstly, Smad1, 
Smad5 and Smad8, activated by ALK1, ALK2, ALK3 and ALK6. Secondly, Smad2 
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and Smad3, which are activated by ALK4, ALK5 and ALK7. 2) The common 
mediator Smad (co-Smad) Smad4, which forms complexes with the R-Smads. 3) The 
inhibitory Smads (I-Smads) Smad6 and Smad7, which oppose R-Smad signaling and 
function (reviewed in Massagué and Chen, 2000; Yue and Mulder, 2001). 
 
1.5.2. Principles for Smad activation 
 
The molecular weight of the Smad proteins ranges from 42 to 69 kDa. These factors 
consist of two highly conserved domains, of which the N-terminal domain is termed 
Mad Homology (MH)1 and the C-terminal domain MH2. The two MH domains are 
linked by a short proline-rich linker region, which appears to participate in the 
crosstalk between Smads and representatives of the mitogen-activated protein kinase 
(MAPK) family (Kretzschmar et al., 1997). In the basal state the MH1 domain of R-
Smads functions as an inhibitor of the MH2 domain by binding to it. The R-Smad 
becomes activated and undergoes a conformational change after ALK receptor-
mediated phosphorylation of its MH2 domain C-terminal SSXS sequence (Macias-
Silva et al., 1996) (Fig. 3). Smad4 and the I-Smads lack this motif and thus cannot be 
phosphorylated by ALKs. The MH2 domain of the activated R-Smads can form 
complexes with other R-Smads of the same signaling class, and will then further 
associate with Smad4. Smad3 is believed to preferentially form trimers, whereas 
Smad2 supposedly also forms dimers. In addition the formation of Smad hexamers 
has been proposed (reviewed in Massagué and Wotton, 2000; Yue and Mulder, 2001). 
The definite stoichiometry of the Smad complexes has not been determined yet. The 
activated Smad complex is able to move into the nucleus where the MH1 domain can 
bind to DNA, either alone (except Smad2 which lack a DNA-binding region) or in 
complexes with several other transcription factors, e.g., Fast-1 in the case of Smad2 
(reviewed in Massagué and Wotton, 2000; Yue and Mulder, 2001). The “Smad anchor 
for activation” (SARA) is a membrane bound protein that has been shown to recruit 
Smad2 and Smad3 to type I receptors by binding to their respective MH2 domains 
(Tsukazaki et al., 1998; Wu et al., 2000). The R-Smads contain a highly conserved 
region, the L3 loop, which determines type I receptor specificity. This region is 
invariant between Smad2 and Smad3, and between Smad1, Smad5 and Smad8, 
respectively (Lo et al., 1998). The L3 loop of Smad4 seems to be critical for its ability 
to form complex with R-Smads (Shi et al., 1997). Smad1 and Smad2 can translocate 
into the nucleus even without Smad4. However, Smad4 seems to be needed in order 
to stabilize the R-Smad-DNA complex and might additionally promote initiation of 
transcription (Liu et al., 1997). 
 
 
 
 
   
 
 
 
 
 
 
Fig. 3. Schematic picture of an R-Smad.  
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Smad6 and Smad7 are inhibitory (I)-Smads, which have been shown to function as 
antagonizers of R-Smad signaling. Smad6 seems to be mainly an antagonist of BMP 
signaling whereas Smad7 has been shown to antagonize signaling by both TGFβ, 
activin and BMPs (Hayashi et al., 1997; Imamura et al., 1997; Nakao et al., 1997a; 
Tsuneizumi et al., 1997; Hata et al., 1998; Hanyu et al., 2001; Liu et al., 2002). Two 
main levels of I-Smad interference with the Smad signaling pathways seem to exist. 
On the one hand, when overexpressed, I-Smads can block Smad signaling by binding 
to the R-Smad-type I receptor interaction site through their MH2 domains (Hayashi et 
al., 1997; Imamura et al., 1997; Nakao et al., 1997a). On the other, at lower 
expression levels, this is not necessarily the case and Smad6 has been shown to 
compete with Smad4 for binding to R-Smads, thus blocking the formation of R-Smad-
Smad4 complexes (Hata et al., 1998). Furthermore, a novel antagonistic mechanism 
for I-Smads has been proposed. The I-Smads have been shown to be present in the 
cell nucleus and it is possible that they bind to and block R-Smad DNA binding sites 
without, however, initiating transcription (Bai and Cao, 2002). The expression of I-
Smads is upregulated after TGFβ family member-induced activation of R-Smads. R-
Smads and I-Smads seem to form a negative feedback loop to possibly prevent 
excessive stimulation of the cell (reviewed in Miyazono, 2002). 
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Fig. 4. Schematic drawing of the signaling chain from ligand binding to Smad 
activation. 
 
1) A ligand (e.g., activin) binds to the 2) constitutively active
type II receptors, which then 3) transphosphorylate the
recruited type I receptors in their GS-domains. 4) An R-Smad
is released from its anchor (SARA), 5) becomes phosphorylated
and forms complexes with Smad4. 6) Ultimately, the Smad-
complex moves to the nucleus where it might bind to DNA and
affect gene transcription. In contrast to activins and TGFβs,
BMP proteins signal by binding simultaneously to type I and II
receptors. 
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1.5.3. Other signaling cascades activated by TGFβ family members 
 
In addition to the Smad signaling pathways there is a rapidly growing body of 
evidence indicating that also members of the mitogen-activated protein kinase family 
(MAPK) cascade can be activated by different TGFβ family ligands. The MAPKs 
include three main groups: the extracellular signal-regulated kinases (ERKs), the c-
Jun-N-terminal kinases (JNKs)/stress-activated protein kinases (SAPKs) and p38. 
These are all intracellular ser/thr kinases, which can be activated within minutes in 
response to extracellular stimuli, e.g., stimulation with TGFβ, and further transmit the 
response to the nucleus. Despite this, a possible direct activation site(s) for MAPKs on 
the type I and/or II receptors has not yet been identified. Interestingly, some MAPKs 
can phosphorylate R-Smads in their proline-rich linker-regions and prevent them from 
entering the nucleus (reviewed in Piek et al., 1999a; Mulder, 2000; Yue and Mulder, 
2001). Thus, a cross-talk between Smads and the MAPKs clearly exists, but more 
studies are needed to determine the precise nature of this interaction. 
 
1.6. Null mice models of ser/thr kinases and Smads 
 
By creating null mice lacking a specific ser/thr kinase receptor or Smad protein, it has 
become possible to study the in vivo involvement of these factors. Knockout mice for 
all five type II and six out of seven type I receptors have been generated thus far. 
Several of the null mice lacking one of the ser/thr kinase receptor die during early 
embryonic development and, not surprisingly, a disruption of a specific Smad is also 
often embryonically lethal (Table 2).  
 
1.7. Ser/thr kinase receptor and Smad involvement in human disease 
 
1.7.1. Tumorigenesis 
 
The anti-mitogenic tumor suppressive effect of TGFβ is lost in several tumor-derived 
cell lines and it has been proposed that mutations in the TGFβ signaling cascade are 
involved in a large fraction of pancreatic and colorectal cancers (reviewed in de 
Caestecker et al., 2000; Massagué et al., 2000). Inactivating mutations of the TGFβ 
type II receptors have been detected in colorectal and gastric cancers (Markowitz et 
al., 1995; Lu et al., 1998). Furthermore, ser/thr kinase receptors are also mutated in 
some hereditary pre-malignant syndromes. Mutations of ALK3 have been shown to 
be responsible for different variants of juvenile polypotic (JP) syndromes, which are 
characterized by the high risk of affected individuals to develop malignant tumors 
from pre-existing benign polyps (Howe et al., 2001; Zhou et al., 2001). Smad 
mutations/deletions have been reported in several cancers, e.g., the chromosomal 
region 18q21 where Smad4 is located is deleted in more than 50% of human 
pancreatic carcinomas (Hahn et al., 1996) and in several colorectal cancers 
(Thiagalingam et al., 1996; Salovaara et al., 2002). Smad4 has also been shown to be 
mutated in a subset of families with juvenile polyposis (Howe et al., 1998) (Table 3). 
 
1.7.2. Other disorders 
 
Mutations of the ALK1 receptor have been shown to cause hereditary haemorrhagic 
telangiectasia (HHT) type 2. The presenting symptoms often include frequent 
epistaxis and patients have mucocutaneous telangiectasia; later in life gastrointestinal 
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bleeding may occur (Johnson et al., 1996). Additionally, arteriovenous malformations 
are sometimes seen. However, these are more common in hereditary haemorrhagic 
telangiectasia type 1, a related more severe disease, caused by mutations in endoglin, 
a TGFβ binding protein (McAllister et al., 1994). Mutations in BMPRII lie behind the 
rare autosomal dominant genetic disorder familial primary pulmonary hypertension 
(FPPH). This disease eventually leads to pulmonary hypertension and cor pulmonale 
by the fifth decade of life (Deng et al., 2000; Lane et al., 2000). The TGFβ family 
member AMH causes regression of the Müllerian ducts in males by binding to 
AMHRII. Patients with an inactivating mutation in the gene for AMHRII will show a 
persistent Müllerian duct syndrome (PMDS) phenotype. These patients are genetically 
males and normally virilized but will also have organs derived from the Müllerian 
ducts, including the uterus, Fallopian tubes and the upper vagina (Imbeaud et al., 
1995) (Table 3). 
 
Table 2. General characteristics of null mice lacking ser/thr kinase receptors and 
Smads. 
 
Factor Null mouse phenotype References 
ALK1 die by E11.5* due to arterio-
venous malformations 
Oh et al., 2000; Urness et al., 
2000 
ALK2 die before E9.5, multiple 
gastrulation defects 
Gu et al., 1999; Mishina et al., 
1999 
ALK3 die at E9.5 Mishina et al., 1995 
ALK4 early embryonic death, impaired 
gastrulation 
Gu et al., 1998 
ALK5 embryonic death before E10.5, 
vascular defects 
Larsson et al., 2001 
ALK6 impaired female reproduction, 
mild chondrogenic defects 
Yi et al., 2000; Yi et al., 2001 
ACVRII  FSH↓, female infertility, 
skeletal defects 
Matzuk et al., 1995a 
ACVRIIB abnormal left-right axis 
formation, die postnatally 
Oh and Li, 1997 
BMPRII  die at E9.5 Beppu et al., 2000 
TGFβRII vascularization defects, 
embryonic death 
Oshima et al., 1996 
AMHRII male pseudohermaphroditism Mishina et al., 1996 
Smad1  die at E9.5, defective allantois 
formation 
Lechleider et al., 2001 
Smad2  embryonic death before E12.5 Nomura and Li, 1998; Waldrip 
et al., 1998 
Smad3** defective immune response, 
colorectal cancer, reduced 
fertility of female mice 
Zhu et al., 1998; Datto et al., 
1999; Yang et al., 1999b; Tomic 
et al., 2002 
Smad4  die before E8.5  Sirard et al., 1998; Yang et al., 
1998 
Smad5 Angiogenetic defects, die 
between E10.5 and E11.5 
Chang et al., 1999; Yang et al., 
1999a 
Smad6  cardiovascular defects Galvin et al., 2000 
 
* E, embryonic day. 
** The Smad3 null mice reported by Zhu et al. had a disruption of exon 2 resulting in colorectal 
cancer, however, the female mice were fertile. In contrast, Smad3 null mice with a deletion of exon 8 
reported by Yang et al. did not develop tumors but the females were later reported to be  infertile.  
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Table 3. Chromosomal loci and human diseases associated with mutated / abnormally 
expressed ser/thr kinase receptors and Smads. 
 
Factor Disease/Disorder Locus References 
ALK1 human hereditary 
telangiectasia 1 
12q11-q14 Johnson et al., 1996; Röijer et al., 
1998a 
ALK2 ? 2q23-q24 Röijer et al., 1998a 
ALK3 juvenile polyposis 10q22.3 Ide et al., 1998; Howe et al., 
2001; Zhou et al., 2001 
ALK4 pancreatic cancer 12q13 Röijer et al., 1998a; Su et al., 
2001 
ALK5 various cancers 9q33-q34 Yoshida et al., 1989; Johnson et 
al., 1995; Yamada et al., 1995; 
Kim et al., 1996; DeCoteau et al., 
1997; Pasche et al., 1998; Wang 
et al., 2000 
ALK6 ? 4q23-q24 Ide et al., 1998 
ALK7 ? 2q24.1-3 Study II 
ACVRII  ? 2q22.2-q23.3 Study I 
ACVRIIB left-right axis malformation 3p22 Ishikawa et al., 1998; Kosaki et 
al., 1999, Study I 
BMPRII  familial primary pulmonary 
hypertension  
2q33 Deng et al., 2000; Lane et al., 
2000 
TGFβRII gastrointestinal cancer 3p22 Mathew et al., 1994; Markowitz 
et al., 1995; Parsons et al., 1995; 
Lu et al., 1998; Tanaka et al., 
2000 
AMHRII persistent Müllerian duct 
syndrome  
12q13 Imbeaud et al., 1995 
Smad1 ? 4q28 Lechleider et al., 1996 
Smad2 
 
colon cancer 18q21.1 Eppert et al., 1996; Riggins et al., 
1996; Nakao et al., 1997b 
Smad3 ? 15q21-q22 Riggins et al., 1996 
Smad4 juvenile polyposis, pancreas 
cancer, colon cancer, 
seminomas 
18q21.1 Hahn et al., 1996; Schutte et al., 
1996; Bouras et al., 2000 
Smad5 ? 5q31 Riggins et al., 1996 
Smad6 ? 15q21-q22 Riggins et al., 1996 
Smad7 systemic sclerosis 18q21.1 Topper et al., 1997; Röijer et al., 
1998b; Dong et al., 2002 
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2. BONE MORPHOGENETIC PROTEINS, RECEPTORS AND SMADS IN 
THE MAMMALIAN OVARY 
 
 
2.1. General characteristics of ovarian function 
 
 
The female ovary plays dual yet closely related roles. On the one hand it is 
responsible for the generation of fertilizable oocytes; on the other it is the main 
production site for the female sex steroids, estradiol and progesterone. The pituitary 
gonadotropins FSH and LH are key players in both events. Even so, during recent 
years it has become evident that also oocyte secreted polypeptides of the TGFβ 
superfamily are needed for normal folliculogenesis in mammals (reviewed in 
Erickson and Shimasaki, 2001; Findlay et al., 2002). Especially the involvement of 
different BMPs and GDF-9 for ovarian function will be discussed below. 
 
2.1.1. Early stages of follicular development 
 
The female gametes are derived from primordial germ cells (PGCs) which is one of 
the first embryonic cell lineages to be established (reviewed in Buehr, 1997). In the 
mouse different members of the BMP family (BMP-2/-4/-8b) were recently shown to 
promote the formation of PGCs from pluripotent precursor cells, but the possible 
involvement of these growth factors for human PGC formation is not presently known 
(Ying et al., 2000; Ying and Zhao, 2001). In humans the germ cells are relocated in 
the gonadal ridges by the fifth week of embryonic development and are then termed 
oogonia. Through mitotic division the oogonia will form clusters surrounded by a flat 
layer of epithelial cells. Some oogonia will be arrested in the prophase of the first 
meiotic division, and are from that stage on referred to as primary oocytes, but the 
majority of the oogonia will continue to grow through mitosis. However, by the 
seventh month most of them will have undergone apoptosis. A single epithelial cell 
layer now surrounds the remaining primary oocytes and this unit is referred to as the 
primordial follicle. Some of these will eventually start to grow already during fetal 
life, but the majority remain in a resting state (reviewed in Buehr, 1997).  
 
2.1.2. Later stages of follicular development 
 
At birth the human ovary contains a bounded number of follicles; some 50 years later 
at the beginning of menopause the number of follicles have diminished to less than 
1000, mainly through apoptotic cell death. Even though some follicles enter the 
growth phase already prior to puberty they undergo apoptosis at an early 
developmental stage because of lack of sufficient levels of gonadotropins. During 
puberty under the influence of FSH, over a growth period of 50 days or more, a 
primordial follicle might eventually become the (usually) single dominant follicle 
destined to ovulate (Fig. 5). As the primordial follicle (φ 30-60 µm) starts to grow its 
surrounding monolayer of flat pregranulosa cells will change to the cuboid granulosa 
cells characterizing the primary follicle. With continuing follicular growth secondary 
follicles develop. The stromal cells of the secondary follicles develop a blood supply 
through angiogenesis. The secondary follicles (φ 80-100 µm) are surrounded by 
several layers of granulosa cells and also the oocytes are larger than those of the 
earlier stage follicles. As the secondary follicles develop, the surrounding layer of 
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stromal cells will differentiate into theca interna and externa cells. Some cells within 
the theca interna differentiate into epitheloid cells, and simultaneously the oocytes 
start to secrete a matrix, which forms the zona pellucida layer. From now on the 
follicle is referred to as a preantral follicle (φ 150 µm) (reviewed in Gougeon, 1996; 
Gougeon, 1998). Follicles are able to grow to these stages without FSH stimulation, 
an event that is referred to as basal follicular growth. The ovaries of patients with an 
inactivating mutation of the FSH receptor gene have primary follicles, whereas 
secondary follicles are rarely found (Aittomäki et al., 1996). Altogether, relatively 
little is known about the regulation of basal follicular growth in humans. Nonetheless, 
some oocyte-derived ligands of the TGFβ family might be indispensable since 
inactivating mutations of the GDF-9 gene in mice (Dong et al., 1996) and the GDF-
9B/BMP-15 gene in sheep (Galloway et al., 2000) lead to an arrest in folliculogenesis 
at the primary stage such that no secondary follicles evolve. 
 
During a time period of approximately two months, the growing preantral follicle 
reaches a diameter of 200-400 µm, now known as the early antral follicle. The 
terminology refers to the fluid-filled cavities, antri, of these follicles, which separate 
the majority of the granulosa cells, referred to as the mural granulosa cells, from 
immediate contact with the oocyte. Two to three layers of granulosa cells, which form 
the cumulus oophorus, still surround the oocyte. Follicles with a diameter of 2-5 mm 
during the late luteal phase form the group of selectable follicles. The number of 
selectable follicles decreases with increasing age; women under the age of 40 have an 
estimated mean of approximately 12-22 selectable follicles per menstrual cycle. One 
of these follicles will then become the dominant follicle destined to ovulate during the 
next menstrual cycle and this selection is accomplished during the subsequent 
follicular phase. The diameter of the selected follicle rapidly increases from 5.5-8 mm 
to the 15-27 mm of the mature pre-ovulatory Graafian follicle (reviewed in Gougeon, 
1996; Gougeon, 1998; McGee and Hsueh, 2000).  
 
2.1.3. The end of the follicular lifespan 
 
In humans the serum levels of LH peak some 36-40 hours prior to ovulation. The 
oocyte completes its meiotic division, and two daughter cells are produced, the first 
polar body and the secondary oocyte, respectively. Only one of them, the haploid 
secondary oocyte, is fertilizable. Soon following ovulation the remaining granulosa 
cells, theca interna cells and invading fibroblasts form a highly vascularized structure 
called the corpus luteum. Under the influence of LH the granulosa cells are luteinized, 
and start to produce progesterone. If pregnancy does not occur within the coming 14 
days, the corpus luteum diminishes and ultimately becomes a corpus albicans. 
However, in the case of pregnancy human chorionic gonadotropin (hCG) secreted by 
the placenta will maintain the corpus luteum for more than four months, after which it 
starts slowly to degenerate (reviewed in McGee and Hsueh, 2000). 
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Fig. 5. Schematic drawing illustrating the major developmental stages of follicles 
during human folliculogenesis. 
 
 
2.1.4. Ovarian steroid hormone production 
 
The ovary is the main production site for the female sex steroids, estradiol and 
progesterone. According to the classical “two cell, two gonadotropin” theory the 
ovarian steroid hormone production requires an intimate co-operation between theca 
and granulosa cells. First, progestin and androgens are synthesized in the theca cells 
under the influence of LH by the combined actions of the cholesterol side chain 
cleavage (P450scc), 17α-hydroxylase (P45017α) and 3β-hydroxysteroid dehydrogenase 
(3β-HSD) enzymes. Second, the androgens are aromatized to estrogens in the 
granulosa cells by P450 aromatase (P450arom), the expression of which is controlled 
by FSH (reviewed in Erickson and Shimasaki, 2001). It is, however, noteworthy that 
both cell types have the capability of producing both androgens and estrogens. 
Nevertheless, the majority of the androgens are synthesized in the theca cell whereas 
the granulosa cells synthesize most of the estrogens (reviewed in Gougeon, 1996).  
 
2.2. Expression of BMPs in the mammalian ovary 
 
The BMPs form the largest subgroup within the TGFβ superfamily. Even though 
originally identified as factors capable of inducing de novo bone growth, these 
multipotent polypeptides are now acknowledged to participate in almost all aspects of 
cellular differentiation (reviewed in Massagué et al., 2000). Recently, at least seven 
members of the BMP/GDF family have been identified in the mammalian ovary. In 
1. primordial follicle 
2. primary follicle 
3. secondary follicle 
4. preantral follicle 
5. preovulatory follicle 
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1989, transcripts of BMP-6 were reported to be expressed in murine oocytes (Lyons et 
al., 1989) and later using Northern blotting the mRNAs encoding BMP-3, BMP-3b 
and BMP-2 were detected in whole rat and/or human ovaries (Hino et al., 1996; 
Takao et al., 1996). Furthermore, BMP-3 has been shown to be expressed in cultured 
human granulosa-luteal (hGL) cells and its expression levels appear to be hormonally 
regulated (Jaatinen et al., 1996). Shimasaki and colleagues have localized the mRNAs 
of BMP-4 and BMP-7 to the theca cells of rat preovulatory follicles (Shimasaki et al., 
1999). GDF-9, a distant relative of the TGFβ superfamily originally cloned in 1993 
(McPherron and Lee, 1993), has been shown to be expressed in rodent (McGrath et 
al., 1995; Fitzpatrick et al., 1998; Joyce et al., 2000), ovine/bovine (Bodensteiner et 
al., 1999) and human oocytes (Sidis et al., 1998; Aaltonen et al., 1999; Teixeira Filho 
et al., 2002). GDF-9 is nowadays considered to be a member of the BMP subgroup of 
the TGFβ superfamily (Vitt et al., 2002). The closely related homologue of GDF-9, 
GDF-9B/BMP-15, is also expressed in the oocytes of various mammals (Dube et al., 
1998; Laitinen et al., 1998; Aaltonen et al., 1999; Galloway et al., 2000; Teixeira 
Filho et al., 2002). 
 
2.2.1. Expression of BMP receptors in the mammalian ovary 
 
BMPs bind to BMPRII in combination with ALK2/3/ or 6, additionally activin type II 
receptors may be used (reviewed in Massagué, 1998). By in situ hybridization ALK3, 
ALK6 and BMPRII have recently been shown to be expressed in rat, murine and 
ovine granulosa cells and oocytes (Shimasaki et al., 1999; Wilson et al., 2001; Yi et 
al., 2001). Furthermore, by immunohistochemical analyses the BMPRII, ALK3 and 
ALK6 proteins have been detected in ovine ovaries (Souza et al., 2002). The BMP 
type II receptor was recently shown to be expressed in hGL cells together with ALK2 
and ALK3 (Erämaa et al., 1995, Study III). ALK3 is a well documented receptor for 
the BMP2/4 subfamily (Koenig et al., 1994; ten Dijke et al., 1994b; Yamaji et al., 
1994; Nohno et al., 1995), whereas the members of the BMP5-8 subfamily also use 
ALK2 and ALK6 for their signaling (ten Dijke et al., 1994b; Ebisawa et al., 1999). 
Several BMPs have further been shown to interact with the activin type II receptors 
(Yamashita et al., 1995), which are abundantly expressed in, for example, hGL cells 
(Erämaa et al., 1995). GDF-9 was recently shown to interact with BMPRII (Vitt et al., 
2002).  
 
2.2.2. Smad expression in the mammalian ovary 
 
Smad3, the first Smad to be shown to display ovarian expression, was originally 
detected in murine granulosa cells by in situ hybridization (Kano et al., 1999). 
Recently, the expression of Smad1-8 in postnatal rat ovaries has been reported 
(Drummond et al., 2002) and the expression levels of Smad2 and Smad3 have been 
shown to fluctuate depending on the developmental stage of the rat follicle (Xu et al., 
2002). More specifically, the expression of both proteins was strong in small follicles 
but almost lost in large antral follicles while Smad2 expression increased again in 
luteal cells (Xu et al., 2002). We have shown by Northern blotting that the transcripts 
for Smads1-6 are detectable in hGL cells (Study III). Human Smad2 and Smad3 
transcripts have been detected in human oocytes by RT-PCR (Österlund and Fried, 
2000) and in human ovarian sections at the protein level (Pangas et al., 2002). Thus, 
its seems evident that all known Smad signaling proteins are expressed in the 
mammalian ovary. 
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2.3. Animal models showing involvement of BMPs for ovarian function  
 
In 1996, the phenotype of mice deficient in GDF-9 was reported. Strikingly, female 
GDF-9 null mice were infertile due to a blockade of folliculogenesis at the primary 
follicular stage, whilst male mice were unaffected (Dong et al., 1996). Interestingly, 
sheep with mutations in the GDF-9B/BMP-15 gene, a close homologue of GDF-9, are 
infertile and their follicles do not develop beyond the primary stage. Moreover, 
heterozygotes for the mutations have an increased ovulation rate resulting in twins 
and triplets, indicating that the dosage of this protein is critical (Galloway et al., 
2000). In contrast to this finding, the reproductive function of female mice with a 
targeted disruption of the GDF-9B/BMP-15 allele is only mildly impaired, resulting in 
slightly lowered fertilization rates (Yan et al., 2001). Recently, hyperprolific Booroola 
ewes were shown to have a mutation in the intracellular domain of their ALK6 
receptors, resulting in a replacement of glutamine for arginine (Q249R) (Mulsant et 
al., 2001; Souza et al., 2001; Wilson et al., 2001). At present, no functional data on 
the bioactivity of the mutated receptor has been published. As mentioned earlier, mice 
deficient in ALK6 show impaired reproductive function even though they appear to 
ovulate histologically mature oocytes. The exact cause is unknown but ALK6 null 
mice show defective cumulus cell expansion combined with prolonged ovulatory 
cycles, which might (in part) explain the condition (Yi et al., 2001).  
 
2.4. Biological effects of recombinant BMPs in the ovary 
 
The in vitro effects of recombinant BMPs have mainly been studied in rodent 
granulosa cell cultures. On their own, BMP-4 and BMP-7 show no apparent effect on 
steroid hormone production in rat granulosa cells. Despite this, both factors have been 
shown to on the one hand stimulate FSH-induced estradiol production, and on the 
other suppress FSH-induced progesterone production (Shimasaki et al., 1999). 
Further, a direct in vivo injection of BMP-7 into rat ovaries resulted in a recruitment 
of primordial follicles into primary, preantral and antral stages; in vitro, BMP-7 was 
shown to act as a granulosa cell mitogen. The in vivo injection of BMP-7 further led 
to significantly fewer ovulated oocytes and lower serum progesterone levels as 
compared to untreated control animals (Lee et al., 2001). BMP-6 is highly expressed 
in oocytes (Lyons et al., 1989), but, knockout mice do not show impaired 
reproductive function (Solloway et al., 1998). Otsuka et al. have demonstrated that 
cultured rat granulosa cells respond to treatment with recombinant BMP-6 protein. 
Like most of the other BMPs tested, BMP-6 on its own did not affect basal steroid 
hormone production. Despite this, unlike BMP-7, BMP-6 was not found to be a 
granulosa cell mitogen. Co-treatment with FSH and BMP-6 inhibited FSH-induced 
progesterone production, without affecting estradiol production (Otsuka et al., 2001b). 
Recently BMP-2 was shown to increase estradiol and inhibin A production in cultured 
sheep granulosa cells, without affecting cell proliferation (Souza et al., 2002). 
 
Several recent studies have described the in vitro effects of the recombinant GDF-9 
and GDF-9B/BMP-15 proteins. Recombinant GDF-9 was found to increase the 
diameter of cultured rat preantral follicles and, moreover, to increase the production 
of the inhibin α-subunit in neonatal rat ovarian explant cultures (Hayashi et al., 1999). 
Using cultured mouse granulosa cells, recombinant mouse GDF-9 was shown to 
induce hyaluronan synthase 2 (HAS2), cyclooxygenase-2 (cox-2), steroidogenic acute 
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regulator protein (StAR) mRNAs as well as progesterone production. On the other 
hand, GDF-9 was found to suppress LH receptor and urokinase plasminogen activator 
(uPA) mRNA expression (Elvin et al., 1999). Recombinant GDF-9 protein caused 
oocytectomized cumulus cell complexes to expand, an affect that was mimicked by 
neither GDF-9B/BMP-15, nor BMP-6 (Elvin et al., 1999; Elvin et al., 2000). In 
cultures of preantral rat granulosa cells GDF-9 is mitogenic and dose-dependently 
downregulates the steroidogenic effects of FSH. On its own, GDF-9 stimulates 
progesterone production in granulosa cells from preovulatory follicles and estradiol 
production in granulosa cells from both small antral and preovulatory follicles, 
respectively (Vitt et al., 2000a). Recently, using cultures of proliferating human 
granulosa and theca cells GDF-9 was found to block the cAMP- and forskolin-
induced synthesis of progesterone and androgens, respectively (Yamamoto et al., 
2002). Intraperitoneal injections of GDF-9 twice daily over a span of 7-10 days in 
immature female rats led to a significant increase in ovarian weight. Histological 
analysis of the ovaries revealed that the number of growing follicles had increased 
(Vitt et al., 2000b). Recently, in line with results derived form rodent studies, GDF-9 
was shown to promote human follicular growth in vitro (Hreinsson et al., 2002).  
 
So far, only one group has reported the successful production of bioactive, C-terminal 
FLAG-tagged, human GDF-9B/BMP-15 recombinant protein (Otsuka et al., 2000). 
The protein was found to stimulate thymidine incorporation in cultured rat granulosa 
cells. When given alone, GDF-9B/BMP-15 did not alter basal steroid production by 
the granulosa cells. However, co-treatment with FSH caused a significant inhibition of 
FSH-induced progesterone production (Otsuka et al., 2000). Further, GDF-9B/BMP-
15 has been shown to suppress FSH-induced steroidogenic enzyme mRNA levels, 
supposedly through downregulation of the FSH receptor mRNAs (Otsuka et al., 
2001c). Recently, follistatin was shown to abolish the biological effects of GDF-
9B/BMP-15, when granulosa cells were co-treated with both proteins (Otsuka et al., 
2001a). It has also been shown that stimulation with recombinant GDF-9B/BMP-15 
induces kit ligand (KL) mRNA expression in cultured rat granulosa cells and that the 
mitogenic effect of this protein is partially dependent on KL (Otsuka and Shimasaki, 
2002). In cultured mouse granulosa cells recombinant GDF-9 has been shown to have 
the opposite effect on KL mRNA expression (Joyce et al., 2000), further indicating 
that the biological effects of GDF-9 and GDF-9B/BMP-15 clearly differ from each 
other. 
 
Table 4. Summary of the mitogenic and steroidogenic effects of BMPs and GDF-9 in 
rodent granulosa cell cultures. 
 
Factor Mitosis Progesterone Estradiol +FSH References 
BMP-4    E↑, P↓ Shimasaki et al., 1999  
BMP-6    P↓ Otsuka et al., 2001b  
BMP-7 ↑   E↑, P↓ Shimasaki et al., 1999, Lee et 
al., 2001  
GDF-9 ↑ ↑ ↑ E↓, P↓ Elvin et al., 1999; Elvin et al., 
2000; Vitt et al., 2000a  
GDF-9B/ 
BMP-15 
↑   P↓ Otsuka et al., 2000  
 
↑ stimulation; ↓ suppression; E, estradiol; P, progesterone 
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3. OVARIAN INHIBINS AND THE REGULATION OF OVARIAN INHIBIN 
SUBUNIT EXPRESSION 
 
 
3.1. Historical background of inhibins 
 
 
The history of the distantly related TGFβ family member inhibin dates back to the 
1920s when its existence was first postulated (Mottram and Cramer, 1923). The 
pituitary of castrated male rats had been found to contain hypertrophic “castrate” 
cells, and it was therefore hypothesized that the testis would normally secret some yet 
unidentified inhibitory factor preventing the development of these cells. By injecting 
an aqueous testicular solution into castrated male rats, the appearance of the “castrate” 
cells was prevented and the factor thought to be responsible was termed inhibin 
(McCullagh, 1932). In the 1970s it was shown that the “inhibin effect” was due to 
suppression of FSH secretion (Setchell and Jacks, 1974). In 1985, four independent 
groups finally reported the molecular structure of inhibin (Ling et al., 1985; 
Miyamoto et al., 1985; Rivier et al., 1985; Robertson et al., 1985). Inhibin was shown 
to consist of an α- and a β-subunit of 18 kDa (in its fully processed form) and 14 kDa, 
respectively, linked together by a disulfide bond (Fig. 5).  
 
α N α C 
α 
 β A 
 β B 
SP pro 
  
 
 
 
  
inhibin  A inhibin  B 
activin  A 
activin  AB 
activin  B 
 
Fig. 5. Schematic drawing of the composition of the proforms of the inhibin subunits 
and the mature forms of dimeric inhibins and activins.  
 
 
Originally two different β-subunits, termed βA and βB were cloned, and both of them 
are expressed in the ovary (Mason et al., 1985). Additionally, three more β-subunits 
termed βC, βD (found in Xenopus) and βE have since been cloned (βC and βE from 
The human inhibin α-subunit can be proteolytically cleaved into a proregion, a larger αN-
fragment and the mature αC-terminal region. The proforms of the inhibin β-subunits are
proteolytically cleaved as well. Inhibins are heterodimers of an α- and a β-subunit, whereas
activins are homodimers of two β-subunits. The two monomers are linked by disulfide bonds to
form dimers (32 kDa inhibin A and 31 kDa inhibin B, with the fully processed α- and β-subunits). 
Ligands & Signaling Components of the TGFβ Family 
 28
liver cDNA libraries), but they appear not to be involved in ovarian function (Hötten 
et al., 1995; Oda et al., 1995; Fang et al., 1996). Soon after the cloning of the inhibin 
subunits, it was observed that the β-subunits could dimerize even in the absence of the 
α-subunit, hence forming a protein called activin, opposing the biological effects of 
the inhibins. Activin was shown to stimulate FSH secretion, thus having the opposite 
effect of inhibin (Ling et al., 1986). 
 
3.2. Intraovarian effects of inhibin 
 
In addition to the sex steroids and gonadotropin-releasing hormone (GnRH), dimeric 
inhibins participate endocrinologically in the control of pituitary FSH release 
(reviewed in Bernard et al., 2002). Furthermore, inhibins are also believed to have 
intragonadal auto/paracrine effects, they have e.g., been shown to augment basic and 
LH-induced androgen production by theca cells in vitro (Hillier et al., 1991b). 
However, since a unique inhibin signal transduction pathway has not been elucidated 
the activity of inhibin in assays may in several cases be interpreted as an inhibition of 
activin activity (reviewed in Bernard et al., 2002). Knockout mice deficient in the 
inhibin α-subunit (and circulating inhibin dimers) develop ovarian tumors of gonadal 
sex cord-stromal origin with 100% penetrance as early as 4 weeks of age (Matzuk et 
al., 1992), indicating that inhibin might function as a potent tumor suppressor within 
the ovary.  
 
3.3. Inhibin receptors 
 
As mentioned previously most TGFβ family members signal via tetrameric 
complexes of cell surface ser/thr kinase receptors. Recent evidence suggest that 
inhibins can form high affinity complexes with betaglycan and ACVRII, thereby 
restricting the number of activin type II receptors available for activin signaling 
(Lewis et al., 2000). Furthermore, the presence of another inhibin binding protein 
(InhBP, originally denoted p120) has been shown (Chong et al., 2000). Even though 
these inhibin binding proteins have been reported, the existence of a specific inhibin 
receptor cannot be ruled out, since the proteins mentioned above are not known to 
activate downstream signaling components in response to inhibin binding (reviewed 
in Bernard et al., 2002). 
 
3.4. Assays for determination of dimeric inhibins  
 
Serum inhibin levels in women were measured already in the late 1980s. Nonetheless, 
the radioimmunoassay used failed to distinguish between different forms of inhibin, 
and it furthermore also detected free α-subunits (McLachlan et al., 1987). After the 
development of highly specific assays for inhibin A and inhibin B, it has been shown 
that these two forms of dimeric inhibins fluctuate in distinct manners during the 
menstrual cycle. Nonetheless, no biological differences are known to exist between 
the two inhibin dimers. Both inhibin assays are based on highly specific monoclonal 
antibodies against the βA- or βB-subunits, respectively. These antibodies are adsorbed 
onto the plate and for detection a monoclonal Fab alkaline phosphatase conjugated 
anti-inhibin α-subunit antibody is used (Groome et al., 1994; Groome et al., 1996). 
The cross-reactivity for the inhibin B ELISA is 0.5% with inhibin A (Groome et al., 
1996). 
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3.5. Inhibin subunit mRNA expression in the rat ovary  
 
In the rat ovary the inhibin α-subunit is expressed in granulosa cells in follicles of all 
stages, whereas the two β-subunits are expressed in primary follicles onwards, but not 
in the corpora lutea (Meunier et al., 1988; Woodruff et al., 1988; Findlay et al., 2001). 
Recently, using a quantitative RT-PCR approach, the relative expression levels of the 
inhibin α-, βA-, and βB-subunits have been determined in postnatal rat granulosa cells 
(Drummond et al., 2000). In line with previous studies the α-subunit was found to be 
produced in excess over the two β-subunits, with its expression levels rising in 
parallel with follicular development. At postnatal day four (primordial and primary 
follicles present) and day eight (preantral follicles present), the mRNA levels of the 
two β-subunits did not differ significantly. In contrast, at day twelve (antral follicles 
present) the mRNA levels of the βA-subunit were twice as high as those of the βB-
subunit. This supports the hypothesis that the βB-subunit would be predominantly 
produced by growing follicles. Furthermore, diethylstilbestrol (DES) treatment of 
immature rats for four days decreased the expression levels of both inhibin β-subunits, 
without affecting those of the α-subunit (Drummond et al., 2000). 
 
3.5.1. Dimeric inhibin levels during the rat estrus cycle 
 
The inhibin dimer-specific human ELISA assays have been shown to be applicable to 
the rat and consequently female rat serum and plasma inhibin levels have been 
determined throughout the four-day rat estrus cycle (Woodruff et al., 1996; Arai et al., 
2002). The serum levels of inhibin A have been found to rise steadily from metestrus 
to peak in proestrus, whereas inhibin B serum levels are quite uniformly elevated in 
metestrus, diestrus and proestrus. Both serum inhibin levels were shown to reach their 
nadir during the secondary FSH surge, which is consistent with their regulatory role 
on FSH secretion. Since both inhibins are elevated at the time of the primary FSH 
surge, GnRH is able to overcome the inhibitory effects of both inhibins. There is a 
strong negative correlation between circulating inhibin B and FSH during the rat 
estrus circle, and it has been suggested that in rodents inhibin B is the primary 
regulator of serum FSH levels (Woodruff et al., 1996). In a more recent study plasma 
inhibin levels were measured and correlated to the ovarian inhibin RNA content (Arai 
et al., 2002). Changes in plasma inhibin concentrations were shown to coincide with 
the expression pattern of the inhibin β-subunit mRNAs with a 3-6 hour-delay (Arai et 
al., 2002) and, furthermore, the plasma inhibin levels measured correlated well with 
the results obtained previously (Woodruff et al., 1996). 
 
3.6. Inhibin subunit expression in the human and primate ovaries 
 
In the human ovary, no mRNA expression for the inhibin subunits has been detected 
in primordial follicles, even though weak immunohistochemical staining has been 
reported for the βA- and βB-subunits (Rabinovici et al., 1992; Yamoto et al., 1992). 
Growing human and primate follicles from preantral up to the preovulatory stage 
show a moderate to high expression of the mRNAs for the inhibin α-subunit and a 
low expression for the βA-subunit, whereas the inhibin βB-subunit mRNA is 
abundantly expressed in granulosa cells from small antral follicles (Schwall et al., 
1990; Fraser et al., 1993; Roberts et al., 1993; Jaatinen et al., 1994). The mRNA 
levels of the βB-subunit fall sharply in preovulatory follicles, accompanied by a 
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marked increase in the levels of the βA- and α-subunits. Interestingly, in addition to 
the granulosa cells, theca cells of human antral follicles also appear to express all 
three inhibin subunit proteins, as recently shown by immunostaining (Pangas et al., 
2002). Human luteinized granulosa cells express all three inhibin subunits, but the βB-
subunit is expressed at almost undetectable levels (Davis et al., 1987; Roberts et al., 
1993; Erämaa et al., 1993). In a recent paper Fujiwara et al. used RT-PCR to 
determine the relative expression levels of the three inhibin subunits in different 
stages of human follicles. The expression levels of the α- and βA-subunit increased 
steadily with concomitant follicular growth, however, in this study no correlation 
between follicle size and βB-subunit expression level was detected (Fujiwara et al., 
2001). Further studies are needed to determine the exact relationship between follicle 
size and inhibin subunit expression levels, but the relative lack of human study 
material remains problematic. 
 
3.6.1. Dimeric inhibin levels during the human menstrual cycle 
 
During the human menstrual cycle the serum levels of inhibin A are low in the early 
follicular phase, rise in the late follicular phase to finally peak one day before the LH 
surge. Thereafter they fall briefly before peaking again in the mid-luteal phase. 
Dimeric inhibin A seems to originate mainly from the preovulatory follicle and the 
corpus luteum (Groome et al., 1994). In contrast to the inhibin A levels, the serum 
concentration of inhibin B is high during the midfollicular phase, decreases 
momentarily before ovulation, and rises shortly two days after ovulation, after which 
it drops to low levels for the rest of the cycle (Groome et al., 1996). Dimeric inhibin B 
therefore seems to be mainly derived from preantral and small antral follicles. In 
humans and primates a clear correlation between serum inhibin B levels and serum 
FSH levels exist especially during the follicular phase and the preovulatory 
gonadotropin surges (Groome et al., 1996). 
 
3.7. In vitro regulation of inhibin subunit expression 
 
The mechanisms regulating differential inhibin A and B synthesis are not thoroughly 
understood (reviewed in Bernard et al., 2001). Gonadotropins acting via cAMP-
dependent pathways are well known stimulators of all three inhibin subunits inhibin 
production in both rodent and human granulosa cell cultures (Bicsak et al., 1986; 
Turner et al., 1989; Hillier et al., 1991a). Since the expression levels of the inhibin α-, 
βA- and βB-subunits vary during different stages of follicular development, and since 
inhibin A and inhibin B have different serum profiles, it has been postulated and 
shown that the expression of each of the three subunits can be differentially regulated 
by local factors including TGFβ family members, leading to a production of either 
dimeric inhibin A or B. The regulation of the expression levels of the inhibin subunits 
has mainly been studied using granulosa cells derived from either immature, 
alternatively diethylstilbestrol (DES)-primed immature rats or, in the case of humans, 
using granulosa-luteal cells obtained from patients undergoing in vitro fertilization 
(IVF) programs (Drummond et al., 2000). 
 
In cultures of rat granulosa cells the inhibin mRNA levels for the α- and βA-subunits 
are upregulated after stimulation with activin A and TGFβ (LaPolt et al., 1989; LaPolt 
et al., 1990). The inhibin α-subunit has also been shown to be upregulated by 
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recombinant GDF-9 in cultures of neonatal rat ovarian explants (Hayashi et al., 1999). 
Furthermore, the production of both dimeric inhibin A and B is upregulated in 
cultures of rat granulosa cells after stimulation with TGFβ or addition of meiotically 
inactive bovine oocytes, a source of, for example, GDF-9 (Lanuza et al., 1999; Sendai 
et al., 2001). This effect is exaggerated in the presence of FSH. Taken together, in the 
rat, several of the tested TGFβ family members appear to upregulate and modulate the 
FSH-induced expression levels of all three inhibin subunits, leading to a production of 
inhibin A and B dimers.  
 
Using cultured hGL cells, activin A and TGFβ have been shown to upregulate the 
mRNA expression levels of the inhibin βB-subunit, whereas gonadotropins 
preferentially stimulate the steady state mRNA levels of the inhibin α- and βA- 
subunits (Erämaa et al., 1995; Erämaa and Ritvos, 1996; Liu et al., 2001). Also, in 
accordance with the mRNA data the production of dimeric inhibin B, but not inhibin 
A, by these cells was increased in response to stimulation with activin A (Vänttinen et 
al., 2000). Based on these studies it appears that the three inhibin subunits are 
somewhat differentially regulated in human and rodent granulosa cells. Whether this 
discrepancy reflects the use of different stage granulosa cells or whether it is an 
interspecies difference is not presently known. 
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AIMS OF THE STUDY 
 
 
At the beginning of this study the following specific aims were set out: 
 
 
• to map all TGFβ family associated ser/thr kinase receptors with unknown 
chromosomal loci together with follistatin, in an attempt to study possible disease 
associations with their respective loci (I and II). 
 
• to search for novel ser/thr kinase receptors (II). 
 
• to determine whether cultured hGL cells express BMP receptors and Smads and, 
further, whether these cells respond to treatment with recombinant BMPs and their 
possible impact on inhibin production (III). 
 
 
At a later stage of the study when new adenoviral tools and recombinant GDF-9 
protein became available additional goals were set: 
 
 
• to study the feasibility of recombinant adenovirus methodology for selective 
overexpression of different ALKs and Smads in hGL cells and their direct impact 
on inhibin production (IV). 
 
• to determine the effects of recombinant GDF-9 protein on inhibin production and 
possible Smad activation in cultured rat granulosa cells (V). 
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MATERIALS AND METHODS 
 
 
Please refer to the individual studies (I-V) and references for more detailed protocols. 
 
1. Human granulosa-luteal cells 
 
Human GL cells were obtained from women in conjunction with oocyte aspiration prior to IVF. The 
ovaries were stimulated by administering a human GnRH analog (Suprecur, Hoechst, Frankfurt am 
Main, Germany) and human recombinant gonadotropin (Puregon, Organon, Oss, The Netherlands or 
Gonal-F, Ares-Serono, Geneva, Switzerland). Thirty-six to 37 h prior to oocyte retrieval patients were 
administered a total dose of 10 000 IU hCG (Pregnyl, Organon or Profasi, Ares-Serono). The granulosa 
cells from 1-6 patients aspirated the same morning were pooled, enzymatically dispersed with 1% 
hyaluronidase (Sigma Chemicals Co, St Louis, MO, USA) in Dulbecco’s Modified Eagle’s Medium 
(DMEM; GIBCO, Grand Island, NY, USA) at 37°C for 30 min. Separation of the granulosa cells from 
erythrocytes was achieved by centrifugation through Ficoll-Paque (Pharmacia Corp., North Peapack, 
NY, USA). After this the cells were either recovered for RNA extraction or plated on plastic culture 
dishes (Greiner Bio-One, Frickenhausen, Germany) at densities specified in studies III-IV and cultured 
in DMEM supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine, 100 IU/ml penicillin 100 
µg/ml streptomycin (GIBCO) at 37°C in a 95% air – 5% CO2 humidified environment. Cell culture 
media were changed every other day until the cells were stimulated with recombinant proteins or 
infected with adenoviruses, as detailed below. 
 
2. Rat granulosa cells 
 
Immature 23 days old female Sprague-Dawley rats were purchased from Simonsen Laboratories 
(Gilroy, CA, USA) and diethylstilbestrol-containing (DES; Sigma) capsules were implanted 
subcutaneously 72 h prior to killing the rats with CO2 (Hsueh et al., 1984). Ovaries were retrieved and 
the follicles were punctured in L-15 Leibovitz medium (Life Technologies, Gaithersburg, MD, USA) 
using 25 gauge needles. After removal of ovarian debris the granulosa cells were collected by 
centrifugation for 10 min at 500 x g after which the cells were dispersed by repeated suspension in 
McCoy’s 5a modified medium (Mediatech, Herndon, VA, USA) supplemented with 2mM L-
glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin (reagents obtained from BioWhittaker, 
Wakersville, MD, USA) and 1 ng/ml recombinant FSH (Puregon, Organon) unless otherwise stated. 
An aliquot of the cells were counted after staining with trypan blue, and finally the cells were cultured 
in Falcon polypropylene tubes (Becton Dickinson, Franklin Lakes, NJ, USA) or plated on 35 x 10 mm 
culture dishes (Beckton Dickinson) at densities specified in study V at 37°C in a 95% air – 5% CO2 
humidified environment. 
 
3. MIN6 cells 
 
MIN6 cells were originally established from mouse insulinomas and this cell line shows several 
morphological characteristics of pancreatic β cells (Miyazaki et al., 1990). Furthermore, it has been 
shown to endogenously express ALK7 (Watanabe et al., 1999). MIN6 cells were cultured on 6-well 
plates (Greiner Bio-One) in DMEM (GIBCO) supplemented with 15% FCS, 100 IU/ml penicillin, 100 
µg/ml streptomycin, 4.5 g glucose/l, 5 µl β-mercaptoethanol/l, 2% HEPES and 3.4 g NaHCO3/l 
(reagents obtained from GIBCO) at 37°C in a 95% air – 5% CO2 humidified environment. 
 
4. 293T cells 
 
Human fetal 293T cells (Graham et al., 1977; DuBridge et al., 1987) were grown in DMEM (GIBCO) 
supplemented with 10% FCS 2 mM L-glutamine, 100 IU/ml penicillin 100 µg/ml streptomycin 
(reagents obtained from GIBCO) at 37°C in a 95% air – 5% CO2 humidified environment in standard 
175 ml plastic culture flasks (Greiner Bio-One). The cells were passaged twice weekly. 
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5. In vitro treatment of cells 
 
To study the activation of Smads and stimulation of inhibin subunits the following recombinant 
proteins were used. Recombinant BMP-2, BMP-3, BMP-3b, BMP-4 and BMP-6 used in Study III were 
gifts from Dr. Rosen (Genetics Institute, Cambridge, MA, USA) and recombinant activin A a gift from 
Dr. Eto (Ajinomoto Inc., Kawasaki, Japan), respectively. In the other studies, recombinant activin A 
and BMP-2 were purchased from R&D Systems (Minneapolis, MN, USA). Recombinant human 
follistatin (288-amino acid follistatin) and hCG were supplied by the National Hormone and Pituitary 
Program (Baltimore, MD, USA) and recombinant FSH from Organon. The production of recombinant 
rat GDF-9 protein has been described (Hayashi et al., 1999). Briefly, 293T cells were transfected with 
an expression vector containing the rat GDF-9 cDNA. Selection of clones stably expressing GDF-9 
was done using Zeocin (Invitrogen, San Diego, CA, USA). Conditioned media were harvested after 4 
days of serum-free culture and finally concentrated. Descriptions of the stimulation media and 
treatment times can be found in studies II-V.  
 
6. Recombinant adenoviruses 
 
High titer stocks of recombinant Smad1/2/6/7, constitutively active (ca) and kinase defective (kd) 
ALK1-7 and LacZ adenoviruses were grown in 293T cells. The original cloning and generation of 
these viruses has been reported earlier (Fujii et al., 1999). Briefly, a kit based on a previously described 
method (Miyake et al., 1996) for making recombinant human serotype 5 adenoviruses was purchased 
from Takara Biomedicals (Takara Shuzo Co., Shiga, Japan). The respective Smad and ALK cDNAs 
were cloned into the vector pAxCAwt, which contains a potent β-actin promoter and cytomegalovirus 
(CMV) enhancers. After preparation of cosmids in competent cells (Eschericia coli), co-transfection of 
the cosmids with adenoviral DNA into 293 cells was performed, after which recombinant adenoviruses 
were generated through homologous recombination. The recombinant adenovirus vector used lack the 
E1 and E3 genes needed for propagation of the virus. However, these genes are provided by 293 cells, 
hence the adenoviruses can propagate in them. For the generation of high titer stocks 293T cells were 
seeded on gelatin-coated culture flasks (Greiner Bio-One). After achieving 50-70% confluency (within 
1-2 days), the cells were infected with the recombinant adenovirus. Within 2-3 days the cells started to 
detach and show cytopathic effects, after which they were harvested and lysed using repeated freezing 
and thawing. These steps were repeated three times and for the final round of amplification twelve 175 
ml culture flasks were used. Purification of the adenoviruses from the final pool of lysed cells was 
achieved by ultracentrifugation for 90 min through CsCl gradients of densities 1.3 and 1.6. The virus 
band was retrieved and purified using PD-10 columns (Pharmacia) and the fraction containing the virus 
was determined using spectrophotometry. Virus aliquots were stored at -80°C in PBS containing 10% 
glycerol. Titrations of the recombinant adenoviruses were performed in 293T cells according to the 
TCID50 method described in the adenovirus manual supplied by Takara Biomedicals 
(http://bio.takara.co.jp/BIO_EN/default.asp). All adenoviral work was carried out in a P2 level 
classified laboratory. Infections of granulosa and MIN6 cells were done in serum-free media for 1-2 h, 
after which the media were changed and the cells were cultured for 8-72 h depending on the 
experiment as detailed in studies II-V. 
 
7. Transfection of rat granulosa cells 
 
Cultured rat granulosa cells were transfected with inhibin-α promoter luciferase and control RSV-β-
galactosidase plasmids under serum-free conditions for 4 h at 37°C using lipofectamine (GIBCO) 
(Felgner et al., 1987). After culturing for 24 h in media supplemented with 1% FCS the cells were 
lysed and the supernatants analyzed using a Monolight 2010 luminometer (Analytical Luminescence 
Lab., San Diego, CA, USA).  
 
8. RNA extraction and preparation of filters 
 
Total RNA from cultured hGL cells or cytoplasmic RNA from freshly isolated hGL cells was extracted 
with the guanidine isothiocyanate-cesium chloride method (Chirgwin et al., 1979) or using the 
modified Nonidet P-40 lysis procedure (Favaloro et al., 1980), respectively. Rat granulosa cell total 
RNA was extracted using an RNeasy extraction kit provided by Qiagen (Valencia, CA, USA). RNA 
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samples were quantitated by absorbance measurement at 260 nm. For Northern blots, indicated 
amounts of RNA were size-fractionated in 1.5% agarose gels, after which they were transferred to 
Hybond-N nylon filters (Amersham Pharmacia Biotech, Little Chalfont, UK). For dot blot studies, 
RNA samples were denatured and spotted onto nylon membranes using a 96-well Minifold device 
(Schleicher and Schuell, Keene, NH, USA). Finally, the filters were baked at 80°C for 1 h prior to UV-
cross-linking for 6 min using a Reprostar II ultraviolet illuminator.  
 
9. Preparation of cDNA probes and hybridizations 
 
Double-stranded cDNA probes were labeled by random priming (Feinberg and Vogelstein, 1983) with 
[α-32P]-α-deoxy-CTP (3000 Ci/mmol; Amersham) using a Prime-a-gene kit (Promega, Madison, WI, 
USA). In the case of the human inhibin βB-subunit a single-stranded cDNA probe was generated using 
PCR as previously described (Erämaa et al., 1995). Purification of the probes was achieved using Nick 
columns (Pharmacia). Hybridizations were performed overnight at temperatures indicated in studies II-
V, in hybridization solution containing 50% formamide, 6 x SSC, 0.1% Ficoll, 0.1% 
polyvinylpyrrolidone, 0.1% BSA, 100 µg/ml salmon sperm DNA, 100 µg/ml yeast RNA and 0.5% 
SDS, or in the case of commercial filters, in hybridization solution provided by the manufacturer 
(Clontech Laboratories, Palo Alto, CA, USA). The probes were used at a concentration of 1-3 x 106 
cpm/ml. The filters were washed two to four times for 20 min with 0.1-1 x SSC, 0.1-1% SDS at 50-
65°C with continuous agitation. For detection the filters were exposed to Fujifilm phosphoimaging 
plates, after which the plates were analyzed using a Fujifilm IP-Reader Bio-Imaging Analyzer BAS 
1500 (Fuji Photo co. Ltd., Tokyo, Japan) and MacBAS software provided by the manufacturer on an 
Apple Macintosh PC (Apple Corp., Cupertino, CA).  
 
10. Western blotting 
 
Prior to Western blotting, the cells were washed once on ice with PBS, after which they were harvested 
in 1× Laemmli-buffer containing 10% β-mercaptoethanol. Cells were gently sonicated on ice for 10 s 
with a Soniprep 150 MSE sonicator (Sanyo Corp., Japan) and boiled for 3 min. Proteins were separated 
on 10-15% SDS-PAGE gels and electroblotted onto Hybond-C membranes (Amersham). For the 
detection of hemagglutinin (HA)-tagged ALK receptors a monoclonal rat anti-HA antibody 
(Boehringer Mannheim, Indianapolis, IN, USA; clone 3F10) was utilized, and for the detection of 
FLAG-tagged Smads a monoclonal anti-FLAG antibody (Sigma; clone M2) was used. The commercial 
antibodies were used according to protocols provided by the manufacturers. For the detection of C-
terminally phosphorylated Smad1 and Smad2, membranes were blocked for 1 h at room temperature in 
TBS-Nonidet P40 containing 2.5% fat free dry milk, after which membranes were incubated with either 
a previously described anti-phosphoSmad1 (αPS1) antibody or anti-phosphoSmad2 (αPS2) antibody 
diluted 1:12000 in TBS-Nonidet P40 containing 2.5% fat free milk at 4 C overnight (Persson et al., 
1998; Piek et al., 1999b). Membranes were washed 3 times for 10 minutes with TBS containing 0.05% 
Tween-20 or Nonidet P-40 prior to incubation for 1 h at room temperature with a secondary anti-rabbit 
antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) diluted 1:14000 in TBS-
Nonidet P40 containing 2.5% fat free milk. After washing four times for 10 min with washing solution 
the immunoreactive proteins were detected using enhanced chemiluminescence (ECL PLUS kit; 
Amersham). 
 
11. Protein content 
 
The protein concentrations of cellular samples lysed with 0.1 M NaOH for 1 h at room temperature and 
neutralized with 0.1 M HCL were measured by the Bradford method (Bio-Rad Laboratories Inc., 
Hercules, CA, USA). 
 
12. Enzyme-linked immunosorbent assay (ELISA) 
 
Commercial ELISAs for the detection of immunoreactive dimeric inhibin A and B in the spent 
granulosa cell media were used according to the manufacturer’s (Serotec Ltd., Oxford, UK) 
instructions. The assays use monoclonal antibodies directed toward the human inhibin βA- and βB-
subunits for capture and a Fab alkaline phosphatase conjugated monoclonal antibody against the human 
inhibin α-subunit for detection. The crossreactivity between the two assays is minimal, approximately 
0.5% for inhibin A in the inhibin B ELISA and < 0.1% for inhibin B in the inhibin A ELISA (Groome 
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et al., 1994; Groome et al., 1996). A signal amplification kit (Life Technologies) was used in 
connection with the ELISAs. To achieve concentrations within the measuring ranges of the assays the 
spent culture medium was diluted with fresh medium. 
 
13. Fluorescence in situ hybridization (FISH) 
 
To obtain clones for FISH we screened a human total genomic P1 artificial chromosome (PAC) library 
(kind gift of Dr. Pieter de Jong, Roswell Memorial Institute, Buffalo, NY, USA) using specific primers 
for human activin type II receptors, follistatin and ALK7. FISH was performed on metaphase 
chromosomes derived from human peripheral blood leukocytes. The cells were cultured according to 
standard protocols and treated with 5-bromo-deoxyuridine (BrdU, 200 µg/ml) at an early replicating 
phase to induce banding pattern (Lemieux et al., 1992). Hybridization with biotin 11-dUTP (Sigma) 
labeled specific clones were carried out in 50% formamide, 10% dextran sulfate in 2 x SSC as 
described earlier (Pinkel et al., 1986; Lichter et al., 1988). Slides were stained with Hoechst 33258 (1 
µg/ml) and exposed to UV light for 30 min, and counterstained with DAPI including antifading reagent 
(Vectashield, Vector Laboratories, Burlingame, CA). A multicolor image analysis was used for 
acquisition, display and quantification of hybridization signals of metaphase chromosomes with an 
system described earlier (Heiskanen et al., 1996). 
 
14. ALK7 cDNA cloning 
 
In a screen for new ser/thr kinases in databases on the Internet (http://www.ncbi.nlm.nih.gov/blast), a 
human genome survey sequence (gss) was found (GenBank AQ129133) showing 83% identity to the 
corresponding sequence of the rat ALK7 gene. PCR primers were subsequently designed to amplify the 
found sequence from human genomic DNA and the amplified PCR fragment was sequenced using an 
ABI PRISM 377 DNA sequencer (Perkin-Elmer, Applied Biosystems, Foster City, CA). A human 
brain ZAP II cDNA library with 9 × 106 independent clones was screened after labeling the PCR 
fragment with the Megaprime DNA labeling system (Amersham). Hybridization was performed in a 
solution containing 50% formamide, 5 x SSC, 5 x Denharts, 0.1% SDS and 50 mg/ml salmon sperm 
DNA overnight at 37°C. The filters were washed in 2 x SSC, 0.1% SDS, twice at room temperature, 
and in 0.2× SSC, 0.1% SDS twice at 55°C. A phagemid vector pBluescript SK(-) with a 3.5-kb insert 
containing the human ALK7 cDNA was obtained by excision from the lambda vector with the helper 
phage R408 as earlier described (Short et al., 1988). 
 
15. Statistical methods 
 
All statistical analyses were performed with Extatics software (Select Micro Sytems, Yorktown 
Heights, NY, USA) on a Macintosh PC. For single comparisons Student’s t test or Mann-Whitney’s U 
test were used and for multiple comparisons one-way analysis of variance (ANOVA) followed by 
Scheffé’s test or Duncan’s multiple range test were applied. Statistical significance was defined as a P 
value ≤ 0.05. 
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RESULTS AND DISCUSSION 
 
 
1. CHROMOSOMAL MAPPING OF HUMAN ACTIVIN TYPE II 
RECEPTORS, FOLLISTATIN AND ALK7 (I AND II) 
 
 
Due to the multitude of developmental defects associated with the loss of activin type 
II receptors and follistatin previously reported in knockout mice (Matzuk et al., 
1995a; Matzuk et al., 1995c; Oh and Li, 1997), we set out to determine the 
chromosomal localizations of the human orthologues. Ultimately we wanted to look 
for possible associations between the chromosomal loci of the orthologues and known 
chromosomal localizations of developmental disorders reminiscent of the respective 
knockout mice phenotypes. Also, since ser/thr kinase receptors mediate growth 
inhibition in a number of cell types, knowledge of their loci is likely to be useful for 
cancer geneticists.  
 
We screened a human total genomic P1 artificial chromosome (PAC) library using 
specific primers for the human activin type II receptors, follistatin and ALK7. After 
labeling of identified positive clones with biotin, we performed FISH on metaphase 
chromosomes and determined the chromosomal localizations of the respective genes 
(as detailed in the Materials and Methods section). 
 
1.1. Activin receptor type II (ACVRII) 
 
We mapped ACVRII to 2q22.2-q23.3 (I, Fig. 1A). However, no known syndromes 
reminiscent of the knockout mice phenotype were found to be associated with this 
chromosomal region. Previous studies on mice deficient in activin type II receptors 
have shown that the lack of this receptor leads to multiple developmental defects. 
Briefly, ~20% of mice with a targeted disruption in the ACVRII gene showed 
alterations in mandible development frequently associated with cleft-palate 
malformations and died soon after birth. Nonetheless, the majority of the ACVRII 
null mice seemed morphologically normal and developed into adults. Among the 
viable mice, the reproductive performance of the female mice was affected and they 
did not undergo normal estrus cycles, probably due to low serum FSH levels. Male 
mice were fertile, even though they had smaller testes than wild-type mice (Matzuk et 
al., 1995a).  
 
1.2. Activin receptor type IIB (ACVRIIB) 
 
The human ACVRIIB gene was mapped to chromosome band 3p22 (I, Fig 1B), and 
the result is in agreement with a report by Ishikawa et al. (1998). ACVRIIB null mice 
have been shown to die postnatally within days. These mice showed severe 
cardiovascular defects including randomized heart position, malposition of the great 
arteries and ventricular and septal defects. Further developmental defects included 
renal abnormalities and an anomalous patterning of the vertebrae (Oh and Li, 1997). 
Double-knockout embryos for the two activin type II receptors died before 
gastrulation, indicating that the two receptors have only partially overlapping 
functions during mammalian development (Oh and Li, 1997). Interestingly, two 
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unrelated patients with the situs inversus syndrome have recently been reported to 
have missense mutations in the ACVRIIB gene (Kosaki et al., 1999).  
 
1.3. Follistatin (FST) 
 
We found that the follistatin gene, which codes for a protein known to bind for 
example activin, inhibin (Nakamura et al., 1990) and GDF9B/BMP15 (Otsuka et al., 
2001a), maps to chromosome band 5q11.2 (I, Fig. 1C). Mice deficient in follistatin 
die within hours postnatally. The phenotype of these mice show growth retardation 
associated with decreased muscle mass, a shiny taut skin, skeletal defects, abnormal 
whiskers and tooth development and ultimately they fail to breathe (Matzuk et al., 
1995c). On the contrary, follistatin-overexpressing transgenic mice show a 
dramatically increased skeletal muscle mass, supposedly through inhibition of 
myostatin activity (Lee and McPherron, 2001). Interestingly, a study reporting a link 
between the chromosomal region 5p14 and the polycystic ovary syndrome (PCOS) 
has been published (Urbanek et al., 1999). The authors considered follistatin as a 
candidate gene for PCOS and subsequently mapped it to this region (5p14), which is 
in disagreement with our results. Therefore, to confirm our own results we obtained a 
human genomic clone of follistatin (kind gift of Prof. Shunichi Shimasaki, University 
of California, USA) and repeated the FISH with this novel probe (unpublished data). 
The results were in accordance with our original, published findings. Furthermore, the 
International Radiation Hybrid Mapping Consortium recently mapped the follistatin 
gene to chromosome 5q (http://www.ncbi.nlm.nih.gov), in agreement with our results. 
Later, Urbanek et al. reported that no mutations were found in the follistatin gene of 
PCOS patients (Urbanek et al., 2000). 
 
1.4. Activin receptor-like kinase 7 (ALK7) 
 
The gene for ALK7 was mapped to 2q24.2-q3 (II, Fig. 3). Some patients lacking this 
chromosomal region have been described. They show severe developmental defects 
but whether this is due to loss of ALK7 is not currently known (Chinen et al., 1996; 
Nixon et al., 1997). A knockout mouse model for ALK7 has not been reported thus 
far. ALK7 is discussed in more detail below. 
 
 
2. SEARCH FOR NOVEL SERINE/THREONINE KINASE RECEPTORS (II) 
 
 
2.1. Cloning and characterization of ALK7 
 
In 1998-2000, when this project was undertaken, it was not known whether the human 
genome would contain novel type I and/or type II ser/thr kinase receptors in addition 
to the previously reported ones. Furthermore, the receptors for the ovary-specific 
ligands GDF-9 and GDF-9B/BMP-15 were unknown, but likely to be ser/thr kinases. 
Therefore, in an attempt to find new receptors we performed Basic Local Alignment 
Search Tool (BLAST®) searches against genomic databases on the Internet 
(http://www.ncbi.nlm.nih.gov/blast) using known ser/thr kinases as templates. We 
identified a human genomic survey sequence (gss), part of which shared 83% 
homology with the transmembrane region of the rat ALK7 receptor. This is a lower 
degree of homology than that shown by the corresponding transmembrane regions of 
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most other human and rodent ALKs. Primers specific for the ALK7 resembling part 
of the gss were designed and PCR was performed using human genomic DNA as the 
template. The derived PCR-product was used for screening multiple-tissue Northern 
blot filters. The expression profile was highly similar to that previously reported for 
the rat ALK7 receptor (Rydén et al., 1996; Tsuchida et al., 1996), being most 
prominent in the brain. Therefore, a brain cDNA library was screened, after which the 
total open reading frame (ORF) for this receptor, the human orthologue of the rat 
ALK7, was obtained. Rat and human ALK7 receptors were found to exhibit a 93.5% 
level of homology in their amino acid sequence (II, Fig. 2). 
 
It has previously been shown that ALK7 is expressed in mouse insulinoma derived 
MIN6 cells, which is in line with the fact that based on a RT-PCR study ALK7 
appears to be the most abundantly expressed type I ser/thr kinase receptor in fetal rat 
pancreatic islets (Watanabe et al., 1999). Therefore, MIN6 cells were chosen for our 
ALK7 signaling studies. An adenovirus with a constitutively active mutant form of 
ALK7 (Ad-caALK7) was obtained and used to infect cultured MIN6 cells. By 
Western blotting the phosphorylation of both endogenous Smad2 and adenovirally 
derived Smad2 by Ad-caALK7 was shown (II, Fig. 4), which is in line with previous 
reports (Watanabe et al., 1999; Jörnvall et al., 2001). The phosphorylation status of 
Smad1/5/8 was not altered by ALK7. Thus, it seems evident that ALK7 signals 
through the same Smads as ALK4 and ALK5, whereas ALK1, ALK2, ALK3 and 
ALK6 form a functionally distinct subfamily. This is in line with the fact that the 
kinase domain of ALK7 is very similar to those of ALK4 and ALK5 (Tsuchida et al., 
1996). However, the extracellular domains of these ALKs are clearly divergent, which 
is in agreement with their different ligand specificities/affinities. 
 
ALK7 was originally cloned as an orphan receptor, without known ligands (Rydén et 
al., 1996; Tsuchida et al., 1996). A recent study by Reissmann et al. showed that 
ALK7 in association with ACVRIIB function as Nodal receptors in the early embryo 
(2001). Nodal has been described as an embryonic protein. Nevertheless, its mRNA 
was recently identified using RT-PCR in the postnatal mouse mammary gland 
(Bianco et al., 2002). To examine whether Nodal would be expressed in the adult 
human we obtained and labeled a human Nodal expressed sequence tag (EST; 
IMAGE clone #5239967) with [α-32P]-α-deoxy-CTP and performed Northern blot 
analyses of multiple human tissue mRNA filters. Even so, no clear expression of 
Nodal mRNA was detected (unpublished data). These results, combined with the fact 
that ALK7 is widely expressed in several tissues in the adult, might indicate that, in 
addition to mediating signaling by Nodal in the embryo, ALK7 serves as the receptor 
for other ligands in the adult. This hypothesis remains to be verified. 
 
2.2. Ovarian ALKs 
 
In parallel to the ALK7 cloning project we set out to clone all ALKs being expressed 
in the ovary. Using cDNA derived from ovaries of two-week-old mice we performed 
PCR, using degenerate primers corresponding to the highly conserved kinase domains 
of the ALKs, in a receptor cloning strategy that has previously been successfully used 
by others (ten Dijke et al., 1993). We sequenced approximately 200 independent 
clones and identified six out of seven known ALKs (Table 5). Sixty-five percent of 
the identified type I receptors were ALK3. However, much caution is needed when 
interpreting these results, since PCR primer stoichiometry might at least partially 
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explain the quantitative differences of different ALKs obtained (unpublished data). 
Taken together these results combined with our database screens and those of others 
(Vitt et al., 2002) suggest that no new type I nor type II ser/thr kinases remain to be 
discovered in the mammalian genome. Therefore, it seems likely that also GDF-9 and 
GDF-9B/BMP15 mediate their effects via a combination of known type I and II 
receptors.  
 
Table 5. Expression pattern of ALKs in two-week-old mouse ovaries. 
 
Ser/thr kinases identified    n 
ALK1        1 
ALK2     16 
ALK3     72 
ALK4       8 
ALK5     13 
ALK6       0 
ALK7       1 
 
 
3. EXPRESSION OF SERINE/THREONINE KINASE RECEPTORS AND 
SMADS IN HUMAN GRANULOSA-LUTEAL CELLS (III AND IV) 
 
 
3.1. Ser/thr kinases 
 
It has previously been shown that hGL cells express the receptors needed for TGFβ- 
and activin-mediated signaling (Erämaa et al., 1994; Erämaa and Ritvos, 1996). The 
expression of a BMP ligand in these cells, BMP-3, has also been observed (Jaatinen et 
al., 1996), but whether these cells would also express BMP receptors was not known 
when our studies were undertaken. To answer this question we performed Northern 
blot analysis and subsequently demonstrated the presence of the BMPRII and ALK3 
receptors, but we failed to detect ALK6 in these cells (III, Fig. 1). The failure in 
detecting ALK6 should perhaps be re-evaluated (e.g., by using RT-PCR) since this 
receptor has recently been shown to be abundantly expressed in both rodent and ovine 
ovaries, and it appears to be needed for female fertility in mice and sheep (Shimasaki 
et al., 1999; Mulsant et al., 2001; Wilson et al., 2001; Yi et al., 2001; Souza et al., 
2002). Using Northern blot hybridization we detected ALK7 mRNAs in the human 
ovary (Study II). However, its localization has not been specifically localized to, for 
example, the hGL cell compartment. Hence, with the possible exception of ALK1, 
ALK6, ALK7 and AMHRII all other type I and II ser/thr kinases appear to be 
expressed in human hGL cells. AMHRII has been reported to be expressed in rat 
granulosa cells of growing follicles, but its expression appears to be lost in the corpus 
luteum (Baarends et al., 1995). In our unpublished experiments we have failed to 
detect AMHRII expression in RNA derived from hGL cells, indicating that its 
expression might be lost in these human luteinized cells. Furthermore, we did not 
detect any Smad activation after stimulation of these cells with recombinant AMH 
(unpublished data). It seems plausible that in the human ovary the expression profile 
of different ser/thr kinase receptors changes with follicular growth, as has recently 
been shown to be the case for the activin receptors (Pangas et al., 2002). 
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3.2. Smads 
 
By Northern blot hybridization analysis we detected mRNA transcripts for the R-
Smads Smad1, Smad2, Smad3 and Smad5 and the common partner Smad, Smad4, in 
unstimulated hGL cells (III, Fig. 1) and by immunohistochemistry we showed the 
presence of the (phosphorylated) Smad1 and Smad2 proteins (IV, Fig. 2). We further 
evaluated how a prolonged culture time would affect the expression levels of the 
Smads. The Smad transcripts were found to steadily decline when compared to the 
expression levels found in freshly isolated cells, an effect most prominently observed 
for Smad3, but not evident for Smad1 nor Smad2 (III, Fig. 1). The inhibitory Smad 
Smad6 was barely detectable in unstimulated hGL cells, but its transcripts were 
induced after stimulation with recombinant BMP-2. Whether Smad7 and Smad8 are 
expressed in these cells has not been shown, however, within the rat ovary Smad8 has 
only been detected in oocytes (Drummond et al., 2002). Taken together our results 
confirm the presence of both TGFβ/activin and BMP signaling machinery 
components in hGL cells. 
 
 
4. STIMULATION OF INHIBIN PRODUCTION IN HUMAN GRANULOSA-
LUTEAL CELLS BY BONE MORPHOGENETIC PROTEINS (III) 
 
 
Previous studies have revealed that activin and TGFβ are selective inducers of the 
inhibin βB-subunit (and dimeric inhibin B) in cultured hGL cells, whereas 
gonadotropins stimulate the expression of the α- and βA-subunits (and dimeric inhibin 
A) in a time- and concentration-dependent manner (Erämaa et al., 1995; Erämaa and 
Ritvos, 1996; Vänttinen et al., 2000; Liu et al., 2001). To test the possible 
involvement of BMPs in inhibin subunit regulation in hGL cells we used recombinant 
BMP-2, -3, -3b and –6. Initial experiments using 50-100 ng/ml of the respective 
ligands revealed that both BMP-2 and BMP-6 (representing two different subgroups 
within the BMP family), but not BMP-3 nor BMP-3b, were able to selectively induce 
the expression of the inhibin βB-subunit in cultured hGL cells. Neither the transcripts 
for the α- nor the βA-subunits were affected by any of the recombinant BMPs tested. 
As shown previously (Erämaa et al., 1995), hCG did not induce the transcripts of the 
inhibin βB-subunit, and it was further shown to suppress the stimulatory effects of 
BMP-2. By treating the cells with 20 µg/ml of cycloheximide for 30 min prior to 
stimulation with BMP-2, we showed that the stimulatory effect of BMP-2 on the 
inhibin βB-subunit was dependent on de novo protein synthesis (III, Fig. 4). 
Furthermore, since follistatin has been reported to block several BMPs, e.g., BMP-4 
and GDF-9B/BMP-15 (Fainsod et al., 1997; Otsuka et al., 2001a), we wanted to 
determine whether it would also block the biological effects of BMP-2. Even though 
follistatin was able to block activin in our hGL assay, not even a 7.3-fold molar excess 
of follistatin was sufficient to block BMP-2-induced stimulation of the expression of 
the inhibin βB-subunit mRNA (III, Fig. 6). Finally we used a specific ELISA assay for 
dimeric inhibin B and showed that BMP-2 stimulated the synthesis of this protein in a 
dose- and time-dependent fashion, in concordance with the RNA data obtained 
previously (III, Fig. 7).  
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In this study (III) we showed for the first time that different BMP members are able to 
evoke a biological response in human granulosa cells. Furthermore we demonstrated 
that BMP receptors and downstream signaling protein Smads are expressed in these 
cells. Several BMPs have recently been identified in mammalian ovaries of different 
species (Lyons et al., 1989; Hino et al., 1996; Jaatinen et al., 1996; Takao et al., 1996; 
Shimasaki et al., 1999), which might indicate that these factors play important roles as 
local auto- or paracrine regulators of inhibin production. Like other TGFβ 
superfamily members studied, including TGFβ, activin A (Erämaa et al., 1995; 
Erämaa et al., 1996; Liu et al., 2001) and GDF-9 (unpublished data), we conclude that 
BMP-2 and BMP-6 also are able to selectively induce the expression of the inhibin 
βB-subunit in cultured hGL cells. Interestingly, recombinant BMP-3 proteins did not 
show any apparent effect, which is well in line with a recent report demonstrating that 
BMP-3 actually might function as an antagonist of BMP-mediated signaling (Daluiski 
et al., 2001). Further experiments should be undertaken to determine whether BMP-3 
functions as an inhibitor of BMP-2-mediated synthesis of dimeric inhibin B also in the 
hGL system. It is also possible that other antagonists of BMP-mediated signaling in 
addition to BMP-3 are expressed in the human ovary, and recent data indicate that 
mRNAs for Bambi/nma are expressed in cultured hGL cells (unpublished data). 
Furthermore, genetic evidence from a strain of sheep where heterozygotes for a 
mutation of the GDF-9B/BMP-15 gene are hyperprolific and homozygotes infertile 
(Galloway et al., 2000), adds further evidence to the belief that the specific “dosage” 
of a certain BMP ligand might be crucial for its biological activity/activities, 
suggesting that specific inhibitors might also be present in the ovary. 
 
We decided to use hGL cells as a model for inhibin subunit regulation since they are 
relatively easily obtainable and all three inhibin subunits are expressed in them, even 
though the expression levels of the βB-subunit are very low (Erämaa et al., 1993). 
Based on our results it is possible that during early human folliculogenesis the heavy 
stimulation of the βB-subunit seen in vivo is achieved by a concerted action of various 
members of the BMP family together with other growth factors such as activin and 
TGFβ. However, when interpreting the results of this study it is important to note that 
the hGL cells used in this study were not derived from small antral follicles, which are 
presumed to be the main expression site of the inhibin βB-subunit during 
folliculogenesis (Schwall et al., 1990; Fraser et al., 1993; Roberts et al., 1993), a 
hypothesis further supported by the rise in circulating inhibin B serum levels seen 
during the beginning of the follicular phase of the human menstrual cycle (Groome et 
al., 1996). Therefore, much caution is needed when drawing conclusions about the 
physiological relevance of the in vitro regulation of the different inhibin subunits 
observed in hGL cells.  
 
A recent study described inhibin subunit regulation in human granulosa cell cultures 
derived from small antral follicles (Welt and Schneyer, 2001). FSH and cAMP were 
found to selectively induce secretion of inhibin A, but not inhibin B, which is in line 
with results obtained from the hGL model. However, in vivo the situation might be 
otherwise, because the rise in serum inhibin B levels during the follicular phase is 
accompanied by a rise in FSH. One possible explanation could be that FSH increases 
the number of granulosa cells, which indirectly results in an increase in the amount of 
dimeric inhibin B being produced. Interestingly, none of the different growth factors 
tested by Welt and Schneyer (activin A, insulin like growth factor (IGF)-I and insulin) 
were able to induce inhibin B production on their own, which is in disagreement with 
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our data. It would be useful to use human granulosa cells derived from small antral 
follicles to determine the role of different BMPs for inhibin B production. These cells 
are, however, not easily obtainable. Nevertheless, it seems evident that in the human 
granulosa cells the production of, on the one hand, inhibin A and, on the other, inhibin 
B are individually regulated. 
 
 
5. OVEREXPRESSION OF ALKS AND SMADS IN HUMAN GRANULOSA-
LUTEAL CELLS STIMULATES INHIBIN B PRODUCTION (IV) 
 
 
Different members of the TGFβ superfamily, such as activin, TGFβ (Erämaa et al., 
1995; Erämaa et al., 1996) and BMP-2 (III), have recently been shown to selectively 
induce expression of the inhibin βB-subunit in cultured hGL cells. The downstream 
signaling of these ligands is mediated through type I ser/thr kinase receptors that 
activate Smad signaling proteins and various MAPK family members in response to 
ligand binding. ALK1/2/3 and 6 are known to activate Smad1, Smad5 and Smad8, 
whereas ALK4/5 and 7 have been shown to activate Smad2 and Smad3. Recently, 
Smads1-8 were shown to be expressed in the rat ovary (Drummond et al., 2002), 
while we have shown that several representatives of the Smad family are expressed in 
the hGL cells (Study III). To investigate the direct effect of type I receptors and Smad 
signaling proteins on dimeric inhibin production we had to find a means of 
overexpressing these factors in cultured hGL cells. These nondividing primary cells 
are exceedingly difficult to transfect by standard liposome-mediated methods (<1% 
cells transfected, unpublished data), wherefore other methods had to be applied. 
Recombinant adenoviruses have been used as gene transfer vectors in numerous 
settings for the in vitro overexpression of a specific gene as well as in clinical gene 
therapy trials. Therefore, we evaluated the feasibility of these viral vectors for gene 
delivery in granulosa cell cultures. First, some general background on the use of 
recombinant adenoviruses will be presented below. 
 
5.1. Recombinant adenoviruses 
 
The discovery and isolation of adenoviruses dates back to 1953 when investigators 
tried to establish cell lines from adenoidal tissues removed from children and military 
recruits (Rowe et al., 1953). Thereafter adenoviruses have been shown to cause a 
multitude of human diseases including upper respiratory tract infection, conjunctivitis 
and gastroenteritis. The human adenoviruses form almost 50 different serotypes, 
which are further divided into six subgroups (denoted A-F). Serotypes 2 and 5 of 
subgroup C are the most commonly used backbones for the generation of recombinant 
adenoviral vectors. The genomes of serotype 2 and 5 adenoviruses consist of 
approximately 36 kilobases (kb) linear double-stranded DNA, which encodes 20-30 
different proteins. The packaging capacity of the virus restricts the insertion of foreign 
cDNAs to approximately 8 kb. The adenoviruses are nonenveloped, icosahedral in 
shape and have a diameter of 60-90 nm (Fig. 6). Adenoviruses infect cells by first 
binding to specific extracellular "coxsackievirus-adenovirus receptors” (CAR) 
expressed on the surface of most cells (Bergelson et al., 1997). After receptor binding 
the complex associates with heterodimeric integrins which allows internalization of 
the virus through endocytosis. Inside the target cell the virus is partially uncoated, 
after which the DNA further migrates to the nucleus where its genes are transcribed to 
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mRNA (reviewed in Yeh and Perricaudet, 1997; Wang and Huang, 2000; Mizuguchi 
et al., 2001). 
 
fibre
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Fig. 6. Schematic drawing of an adenovirus.  
 
 
After cellular transduction the adenoviral early transcriptional genes (E1-E4) are first 
transcribed. These are responsible for viral gene transcription, DNA replication, host 
immune suppression and inhibition of apoptosis of the infected cell (reviewed in 
Wang and Huang, 2000). The recombinant adenoviruses used in this study have 
deletions in E1 and E3, which prevent them from propagating in ordinary cells. E1 is 
absolutely needed for propagation whereas E3 encodes proteins associated with host 
defense mechanisms and is not needed for virus propagation (reviewed in Mizuguchi 
et al., 2001). For the generation of high titer virus stocks effective propagation of the 
virus is needed. This is achieved by infecting, for example, 293 or 911 cells that 
stably express the early transcriptional genes needed (E1) and, after concentration, 
virus stocks containing up to 1012 particles/ml can be achieved (reviewed in Wang 
and Huang, 2000). 
 
5.2. Overexpression of adenovirally derived proteins in hGL cells 
 
We used 293T cells to grow high titer stocks of different recombinant adenoviruses, 
including constitutively active and kinase defective ALKs and wild type Smads (Fujii 
et al., 1999). We found that human granulosa cells were very susceptible to 
adenoviral infection, indicating that they express high levels of adenoviral receptor 
molecules. Already a multiplicity of infection (m.o.i) value of one or even less 
produced in most cases a detectable amount of adenovirally derived protein (IV, Fig. 
1). When m.o.i. values >300 were used the granulosa cells started to show cytopathic 
effects and detached from the plastic within 24 h, hence lower concentrations of 
viruses were routinely used. Primary luteinized granulosa cells form an optimal target 
for adenovirally-mediated gene transfer since they do not propagate in vitro and 
consequently the expression level of the transduced gene is not “diluted” by cell 
division. The expression of the virally derived gene product was detectable starting at 
6 h post-infection and peaked 1-2 days post-infection. To our knowledge this was the 
first time recombinant adenoviruses were used to infect human granulosa cells in 
culture. Nonetheless, this technique has recently been applied to rat granulosa cells in 
The protein shell is
composed of 252 subunits,
called capsomeres (240
hexons and 12 pentons).
The viral genome consists of
double stranded DNA,
which is associated with a
protein complex (terminal
protein). 
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culture (Somers et al., 1999; Bebia et al., 2001). We first infected cultured hGL cells 
with adenoviruses encoding constitutively active mutants of ALK1-7. The expression 
of the adenovirally-derived proteins was routinely confirmed by immunoblotting with 
antibodies against specific C-terminal tags (HA and FLAG for ALKs and Smads, 
respectively). We next showed these receptors to be biologically active by 
immunoblotting against phosphorylated Smad signaling proteins 6-12 h post-infection 
with a caALK virus (IV, Fig. 2). It seems evident that ALKs phosphorylate Smads in 
granulosa cells in the same way as has previously been observed in numerous other 
types of cells. We further wanted to examine the effect of caALK overexpression on 
the production of dimeric inhibin B. All seven ALKs were found to stimulate the 
production of inhibin B, the effect being most profound for ALK4 and ALK5 (IV, 
Fig. 4). This might be due to the fact that granulosa cells produce small amounts of 
activin and TGFβ, which in an auto/paracrine manner further stimulate the 
overexpressed type I receptor, leading to an “additive” effect on inhibin B production. 
 
Interestingly, when Smad1 and Smad2 were overexpressed alone they were shown to 
become phosphorylated independently of addition of exogenous ligands (IV, Fig. 5). 
Others have recently addressed the reason for this intriguing finding known from 
numerous in vitro studies. It was shown that in the case of Smad3, SARA might serve 
as a guardian preventing monomeric Smad3 from forming activated trimers in the 
absence of proper ligand stimulation. High levels of overexpressed Smad3 possibly 
overcome the limits of SARA of preventing them from becoming aberrantly activated 
(Qin et al., 2002). But, whether this or similar mechanisms also apply for 
overexpressed Smad1 and Smad2 remains to be shown in the future. 
 
The production of inhibin B was clearly stimulated after overexpression of Smad1 and 
Smad2 (IV, Fig. 5). This is in line with our previous results indicating that both 
TGFβ/activin- and BMP-activated signaling pathways converge on the same final 
stage, the stimulation of inhibin B production (Erämaa et al., 1995; Erämaa and 
Ritvos, 1996, Study III). In our unpublished results the stimulatory effect on dimeric 
inhibin A production by caALK1-7 was minimal, which is in line with RNA and 
protein data previously obtained by us and others (Erämaa et al., 1995; Erämaa and 
Ritvos, 1996; Tanimoto et al., 1996; Vänttinen et al., 2000; Liu et al., 2001, Study 
III). Finally, Smad7 overexpression effectively shut off the stimulatory effects of 
activin and BMP-2 on inhibin B production (V, Fig. 7), further indicating that Smads 
might participate in the regulation of inhibin production in hGL cells. 
 
 
6. STIMULATION OF RAT GRANULOSA CELLS WITH GROWTH 
DIFFERENTIATION FACTOR-9 (V) 
 
 
The aim of this part of the study was to determine whether treatment with 
recombinant GDF-9 would stimulate inhibin production in rat granulosa cells. 
BMPRII was identified by our collaborators to be a receptor for GDF-9 during the 
course of this study (Vitt et al., 2002) and it was further anticipated that GDF-9 
stimulation of the granulosa cells would lead to R-Smad phosphorylation. Even so, 
whether the Smads would be of the activin/TGFβ or the BMP subgroup was not 
known prior to this study.  
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The mRNA levels of the inhibin α- and β-subunits have previously been shown to be 
upregulated in rodent granulosa cells by gonadotropins (Zhang et al., 1987; Turner et 
al., 1989) and several growth factors, including TGFβ and activin (LaPolt et al., 1989, 
LaPolt, 1990). It is important to realize that inhibin β-subunits can also dimerize to 
form activins, since at equimolar ratios of α- and β-subunits mainly activin is formed. 
Therefore one cannot necessarily interpret whether dimeric inhibin is being produced 
on the basis of inhibin subunit expression (Meunier et al., 1988). Mice deficient in 
GDF-9 have up to a three-fold increase in circulating FSH-levels (Dong et al., 1996), 
but whether this is caused by a decrease in circulating inhibin levels is not known. 
Furthermore, GDF-9 has been shown to stimulate the inhibin α-subunit content in 
explants of neonatal rat ovaries (Hayashi et al., 1999), but whether GDF-9 would also 
affect the transcription levels of the two β-subunits and, further, the production of 
inhibin dimers was not known prior to this study.  
 
6.1. Production of dimeric inhibins in response to GDF-9 stimulation of rat 
granulosa cells 
 
We used recombinant rat GDF-9 protein as well as recombinant human FSH and 
showed both of them to be inducers of the production of dimeric inhibin A and B 
protein, as well as the expression levels of all of the three inhibin subunit mRNAs (V, 
Fig. 1 and 3, respectively) in cultured rat granulosa cells. Interestingly, when 
administered together GDF-9 and FSH showed a supra-additive effect on dimeric 
inhibin production. The synergistic effect of GDF-9 and FSH was not observed at the 
mRNA level, suggesting that posttranscriptional actions of GDF-9 on inhibin 
synthesis might exist. Because recombinant rat inhibin standards are presently 
unavailable, the inhibin levels were measured against human standards. It is therefore 
noteworthy that the absolute inhibin concentrations measured possibly underestimate 
the real levels. Nonetheless, the changes in the ratios are likely to be maintained even 
if the inhibins were measured against rat inhibin standards (Lanuza et al., 1999).  
 
To further decipher the stimulatory effects of GDF-9 on inhibin α-subunit expression, 
we transiently transfected rat granulosa cells with an inhibin α-subunit promoter-
luciferase construct. Treatments with GDF-9, as well as with FSH, were shown to 
stimulate the inhibin-α gene promoter, but the combined effect was less than additive 
(V, Fig. 5). Interestingly a recent report indicated that women with PCOS might have 
aberrant expression of GDF-9 mRNAs (Teixeira Filho et al., 2002). It has furthermore 
been reported that PCOS patients may have up to 16-fold lower inhibin α-subunit 
mRNA expression within a single follicle as compared to similar-sized follicles of 
control patients, but whether this is due to the decreased expression of GDF-9 is not 
currently known (Fujiwara et al., 2001). In contrast, GDF-9 knockout mice have 
normal or slightly elevated inhibin α-subunit mRNA expression, whereas the 
expression of the βB-subunit mRNAs are dramatically decreased. Whether the slightly 
elevated FSH-levels seen in this animal model are due to low circulating levels of 
inhibin B has not been shown (Elvin et al., 1999).  
 
Lanuza et al. have previously demonstrated the production of the two inhibin dimers 
to be differentially regulated in cultured granulosa cells derived from immature DES 
treated rats (1999). Under basal conditions a preference for the production of inhibin 
A over inhibin B was seen; moreover, the basal production of both inhibins was 
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clearly enhanced with addition of FSH to the media. TGFβ and activin A were found 
to preferentially stimulate the production of inhibin B, even though inhibin A levels 
were increased as well. Co-treatment with FSH and TGFβ led to an augmented 
stimulatory effect on both inhibin dimers. Furthermore, the addition of 15 freshly 
isolated bovine oocytes per culture well stimulated the production of inhibin B 100-
fold and inhibin A 10-fold over control levels during 72 h culture. Since bovine 
oocytes, among other growth factors, have been found to express GDF-9 
(Bodensteiner et al., 1999; Sendai et al., 2001) it is indeed possible that the effect seen 
on inhibin production was induced by this growth factor.  
 
To study the impact of TGFβ on dimeric inhibin production in the native unstimulated 
ovary, cultures of post-natal ovarian cells derived from 4-, 8- and 12-day-old rats have 
been used (Drummond et al., 2000). In ovaries of various age it was shown that 
inhibin A was produced in excess over dimeric inhibin B, as is the case in granulosa 
cells derived from DES-treated rats (Lanuza et al., 1999). Ovarian cells from 4-day-
old ovaries, which are rich in small primordial and primary follicles, mainly produce 
dimeric inhibin A when stimulated with TGFβ. Cell cultures containing granulosa 
cells derived from larger preantral and antral ovaries (8- and 12-day-old ovaries, 
respectively) were able to produce both dimeric inhibin B and A after stimulation with 
TGFβ (Drummond et al., 2000). Thus the differentiation state of the follicles seems to 
determine what form of dimeric inhibin is produced. 
 
In our own unpublished experiments we stimulated cultured hGL cells with 
recombinant rat GDF-9. As has previously been shown when stimulating hGL cells 
with TGFβ, activin and different BMPs (Erämaa et al., 1995; Erämaa and Ritvos, 
1996; Vänttinen et al., 2000; Liu et al., 2001, Study III), GDF-9 also selectively 
upregulated the expression levels of the inhibin βB-subunit and further stimulated the 
production of dimeric inhibin B in a concentration- and time-dependent manner. This 
is clearly in contrast to the rat model, where we showed GDF-9 to upregulate the 
mRNA levels of all three inhibin subunits as well as to stimulate the production of 
both dimeric inhibin A and B (Study V). It is therefore important to acknowledge that 
there appear to be fundamental differences in the regulation of the three inhibin 
subunits in humans as compared to rodents. Whether this is caused by interspecies 
differences or by differences in the granulosa cell models used remains to be 
elucidated. Presently no biological differences between the two inhibin dimers are 
known and hence the possible physiological need for different dimeric inhibins 
remains to be shown. 
 
6.2. GDF-9 receptor signaling is mediated via Smad2  
 
Previous studies have revealed that both the rat and human inhibin α-subunit 
promoters contain cAMP-response elements (CRE) (Pei et al., 1991; Schmitt et al., 
2002). This is in the line with the fact that both FSH and pharmacological agents 
capable of increasing the intracellular content of cAMP (e.g., forskolin) are potent 
inducers of the inhibin α-subunit (Zhang et al., 1987; Turner et al., 1989). Since 
treatment of granulosa cells with recombinant GDF-9 stimulated the inhibin α-subunit 
promoter (V, Fig. 5), yet does not induce the production of intracellular cAMP (Vitt et 
al., 2000a), we set out to determine whether other downstream factors would be 
activated after stimulation with GDF-9. More specifically, we wanted to determine 
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whether intracellular Smad signaling proteins would be phosphorylated after 
treatment with GDF-9.  
 
Recombinant GDF-9 protein was recently demonstrated to bind to BMPRII 
ectodomains (Vitt et al., 2002). Furthermore, by blocking the expression of 
endogenous BMPRII mRNAs using antisense oligos in cultured rat granulosa cells, 
the stimulatory effect of GDF-9 on granulosa cell proliferation as measured by 
thymidine uptake was abolished (Vitt et al., 2002). It is not, however, presently 
known what type I receptors GDF-9 might use for its signal transduction. BMPRII has 
previously been shown to form complexes with ALK2, ALK3 and ALK6 in 
mammalian cells (Koenig et al., 1994; Kawabata et al., 1995a). 
 
Based on the known receptor binding data it was anticipated that GDF-9 stimulation 
would also lead to stimulation of the BMP-Smads, Smads1/5/8, through recruitment 
of one of the above mentioned BMP type I receptors. To address this question we 
cultured rat granulosa cells and subsequently stimulated them with different 
concentrations of recombinant GDF-9. Quite surprisingly, like activin A, GDF-9 was 
shown to time- and dose-dependently induce the expression of a 52 kDa protein, 
which was detected using an antibody against C-terminally phosphorylated Smad2. In 
contrast to BMP-2, stimulation with GDF-9 did not induce phosphorylation of Smad1 
(V, Fig. 4). Hence, it seems likely that GDF-9 binds to a receptor complex consisting 
of BMPRIIs and either ALK4, ALK5, or, perhaps based on its expression pattern less 
likely, ALK7 (Table 6). BMPRII has been shown to interact with ALK5 in yeast, but 
to date this interaction has not been shown in mammalian cells (Kawabata et al., 
1995b). Interestingly Smad2 and Smad3 but no activin type II receptor proteins were 
recently shown to be expressed in rat primary follicles (Drummond et al., 2002). This 
indicates that some other factor than activin (e.g., GDF-9) might utilize these 
signaling intracellular proteins during early stages of folliculogenesis. 
 
 
Table 6. Type I and type II receptors and some examples of ligand binding.  
 
 TGFβRII BMPRII ACVRII ACVRIIB AMHRII 
ALK1 TGFβ 
 
    
ALK2  BMP-7 BMP-7 
Activin 
BMP-7 
Activin 
AMH 
ALK3  BMP-2 
BMP-7 
BMP-2 
BMP-7 
BMP-2 
BMP-7 
AMH 
ALK4  GDF-9? Activin  
 
Activin  
 
 
ALK5 TGFβ GDF-9? 
 
   
ALK6  BMP-2 
BMP-7 
BMP-2 
BMP-7 
BMP-2 
BMP-7 
AMH 
ALK7  GDF-9??  Nodal 
 
 
 
 
Since stimulation with GDF-9 does not increase intracellular cAMP content (Vitt et 
al., 2000a), it is likely that intracellular Smad signaling proteins activated by GDF-9 
type I receptors might participate in the stimulation of the inhibin α-subunit promoter 
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(Fig. 7). We did indeed locate a CAGA consensus sequence in the rat inhibin α-
subunit promoter, and Smad3 has been shown to bind to this Smad binding element 
(SBE) (Dennler et al., 1998). It is highly likely that stimulation with GDF-9 also leads 
to Smad3 phosphorylation, which could bind directly to the SBE of the inhibin α-
promoter. However, this issue remains to be shown in future studies. 
 
 
 
Smad2  Smad2  Smad2  Smad2-P  
GDF-9 
II 
I 
P P 
Smad4 
Smad4 
SBE CRE 
Transcription 
inhibin  α 
nucleus 
cytoplasm 
Smad3-P? Smad2-P 
Smad2-P 
Smad3 Smad2 
 
 
Fig. 7. Possible mechanism for inhibin α-subunit gene activation by GDF-9.  
 
 
Our unpublished experiments have further shown that in cultured hGL cells GDF-9 
activates Smad2, consistent with the rat model. Interestingly, stimulation with 
recombinant GDF-9 also appears to lead to Smad2 phosphorylation in various non-
ovarian cell lines tested (e.g., 293 cells). This indicates that the receptor combination 
used is not fully ovary-specific in contrast to the biological effects of GDF-9, which 
appear to be tightly restricted to the ovary (Dong et al., 1996). What then keeps GDF-
9 ovary-specific if its receptors are abundantly expressed in various tissues? Several 
possibilities exist. One is the existence of some intraovarian yet unindentified 
component which increases the affinity of GDF-9 for its receptors (e.g., analogous to 
Cripto in ALK4 mediated Nodal signaling, Reissmann et al., 2001), thus preventing it 
from “leaking” to the circulation and binding to non-ovarian BMP type II receptors. It 
might also be that the half-life of GDF-9 is short in vivo, wherefore it can only act in 
an auto/paracrine fashion because of rapid inactivation. The lack of the fourth cysteine 
that is utilized in dimerization suggests that GDF-9 dimers might not be very stable 
(McPherron and Lee, 1993). A fourth possibility is the existence of GDF-9 binding 
Extracellular GDF-9 protein binds to BMPRII and
possibly simultaneously to type I receptors, alternatively
GDF-9 binds first to the type II receptors, after which type
I receptors are recruited to the complex. The type II
receptors transphosphorylate the type I receptors, which
in turn phosphorylate Smad2 (and most likely Smad3)
signaling proteins, which in complexes with Smad4 enter
the nucleus to affect gene transcription by binding to
SBEs, e.g., CAGA. 
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proteins, however, at least follistatin does not seem to block the biological activities of 
GDF-9 (unpublished data).  
 
A detailed understanding of the regulation of inhibin biosynthesis across 
folliculogenesis is important as it may shed light on pathophysiological conditions 
where follicular development is disrupted. Finally, as it is becoming clear that GDF-9 
and GDF-9B/BMP-15 signaling pathways play essential roles in early mammalian 
folliculogenesis (Dong et al., 1996; Galloway et al., 2000), future studies will be 
needed to elucidate the complete signaling machinery utilized by these factors. Also 
the possible activation of other intracellular signaling proteins working in parallel to 
the Smads needs to be investigated. 
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SUMMARY AND CONCLUDING REMARKS 
 
 
The members of the TGFβ superfamily are involved in a plethora of cellular events 
and their signaling machinery involves a set of markedly conserved transmembrane 
type I and II ser/thr kinase receptors and intracellular Smad proteins. Recent data 
indicate that several TGFβ superfamily members are vitally important for normal 
ovarian function and, furthermore, that they might participate in the regulation of 
inhibin production. We set out to study some of these growth factors and their 
receptor molecules with special emphasis on their role for ovarian inhibin production. 
On the basis of the results obtained during the course of this thesis study the following 
conclusions can be drawn: 
 
• The chromosomal loci for the ACVRII, ACVRIIB, ALK7 and follistatin genes 
were determined using FISH. Even though we did not identify clear disease 
associations to their chromosomal loci this knowledge will undoubtedly support 
further studies. 
 
 
• We identified and cloned the human ALK7 cDNA and found its mRNA to be 
widely distributed in most adult tissues. In human tissues, the expression of Nodal, 
the receptor’s sole known ligand, appears to be restricted to the embryo. Future 
studies will be needed to determine whether other ligands use ALK7 for their 
signaling. Despite extensive searches no novel type I nor type II ser/thr kinases 
were discovered. 
 
 
• We first identified the transcripts of several BMP Smads and ser/thr kinases in 
human ovarian granulosa cells. Secondly we showed for the first time that various 
BMPs are able to selectively induce expression of the inhibin βB-subunit, and 
furthermore, production of dimeric inhibin B in cultured hGL cells. The 
stimulatory effect of the BMPs was suppressed by gonadotropins. It would be 
useful to study the effect of BMPs in cultures of granulosa cells derived from 
small antral follicles, since these are thought to be responsible for the production 
of the majority of inhibin B in vivo. Furthermore, our results point out the possible 
involvement of the BMP signaling pathway in human ovarian physiology. 
 
 
• We showed that hGL cells could be effectively transduced with recombinant 
adenoviruses. Applying this novel methodology we selectively overexpressed all 
seven ALKs and various Smads in cultured hGL cells and showed that 
overexpression of the constitutively active ALKs lead to Smad phosphorylation 
and stimulation of dimeric inhibin B production. A similar effect was obtained 
after overexpression of Smad1 and Smad2, whereas Smad7 was able to block the 
stimulatory effect of both activin A and BMP-2 on inhibin production. Taken 
together our results indicate that R-Smads directly stimulate inhibin B production 
in these cells.  
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• Using cultured rat granulosa cells we demonstrated that GDF-9 stimulates the 
production of all three inhibin subunits as well as of dimeric inhibin A and B. This 
indicates that also in the human GDF-9 participates in the complex regulation of 
inhibin production. GDF-9 produced by the oocyte may act by stimulating the 
granulosa cells to produce inhibin, which might downregulate pituitary FSH 
secretion, thus affecting the progression of folliculogenesis. Finally, GDF-9 
treatment of rat granulosa cells also leads to specific phosphorylation of Smad2, 
hence an emerging line of evidence indicates that ALK4, ALK5 or ALK7 
participate in the functional receptor complex together with the GDF-9 type II 
receptor, BMPRII. Studies have been initiated to address which of these receptors 
are needed for GDF-9 mediated signaling. 
 
 
• It is clear that further studies are needed to define the whole GDF-9 receptor 
complex at the molecular level. Since recombinant GDF-9 in the future might 
have the potential for being used in infertility treatments, in particular for 
stimulation of follicular growth in vitro, a thorough understanding of its means of 
action is of fundamental importance. Equally interesting would be to block the 
effects of GDF-9 and hence prevent the progression of folliculogensis at the 
primary stage, which could lead to the development of a novel non-steroidal 
contraceptive.  
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